Literature DB >> 35187318

Selective Synthesis of Azoloyl NH-1,2,3-Triazoles and Azolyl Diazoketones: Experimental and Computational Insights.

Yuri M Shafran1, Aqeel A Hussein2, Nikolai A Beliaev1, Vadim A Shevyrin1, Sergey Shityakov3, Tetyana V Beryozkina1, Vasiliy A Bakulev1.   

Abstract

Here, we report that the reaction of enaminones, from a class of azole series, with sulfonyl azides leads to a difficult-to-separate mixture of two pairs of compounds: (1) 4-azoloyl-NH-1,2,3-triazoles with sulfonamides and (2) azolyl diazoketones with N-sulfonamidines, as a result of the implementation of two competing reactions. On one hand, the electron-donating methyl or methoxy group in the aryl para-position of arylsulfonyl azides favors the production of NH-1,2,3-triazoles together with sulfonamides. On the other hand, the use of highly electrophilic 4-nitrophenylsulfonyl azide promotes the formation of diazoketones and sulfonamidines. It is shown that the direction of each reaction is not only controlled by the nature of the initial enaminones and sulfonyl azides but also depends on the tested solvent. The problem of removing sulfonamides and amidines from the desired products was solved for the first time using new water-soluble enaminones. Based on the experimental and computational studies, the factors contributing to the selective course of alternative reactions were identified, and methods for the synthesis of azoloyl-NH-1,2,3-triazoles and azolyl diazoketones were developed. Density functional theory (DFT) results have shown that the 1,3-dipolar cycloaddition is totally driven toward one single regioisomer with a high asynchronous bond formation, and the introduction of an electron-deficient group in sulfonyl azides induces faster cycloaddition. Additionally, DFT calculations were used to gain further mechanistic insights on the reaction studied here.
© 2022 The Authors. Published by American Chemical Society.

Entities:  

Year:  2022        PMID: 35187318      PMCID: PMC8851643          DOI: 10.1021/acsomega.1c05898

Source DB:  PubMed          Journal:  ACS Omega        ISSN: 2470-1343


Introduction

NH-1,2,3-Triazoles, linked to a second five-membered heterocycle through a carbonyl group, possess two active functional groups and are therefore promising building blocks for obtaining various 1,2,3-triazole derivatives. 1,2,3-Triazole is a heterocycle that has found wide applications as a privileged scaffold in the directed synthesis of substances with biological activity, in organic electronics for the synthesis of new materials, as a key fragment in the synthesis of substances capable of metal-catalyzed cycle transformations, and as a unique building block in the synthesis of various organic compounds.[1,2] Among NH-1,2,3-triazoles, substances with biological activity and used as new materials with interesting optical and physical properties were also found.[3−10] The primary methods of synthesis of 4-carbonyl derivatives of NH-triazoles include reactions of acylacetylenes with inorganic azides,[11−14] interaction of α-diazo-β-oxoaldehydes with aniline, ammonium, hydroxylamine, and semicarbazide,[15] and modifications of ready NH-triazoles synthesized by other methods.[16,17] All the methods mentioned above almost completely focused on the production of 4-aroyl derivatives of 1,2,3-triazole. In this aspect, another method based on the reaction of β-enaminones 1 with tosyl azide (2a) is an exception, which permitted to prepare three 4-heteroaroyltriazoles (pathway A, Scheme ).[18−20] Thus, the existing synthesis methods are limited in their applicability for the production of 4-heteroaroyl-NH-triazoles.
Scheme 1

General Scheme of Synthesis of NH-Triazoles 4 and Diazo Compounds 5 from Enaminones 1 and Azides 2

It should be noted that changing the nature of enaminones 1 and the conditions of their reaction with sulfonyl azides 2 lead to switching to other products, diazoketones 5 together with amidines 7 (pathway B, Scheme ).[21] α-Diazoketones are widely used in organic synthesis. They are well-known precursors of carbenes and carbenoids. Being 1,3-dipoles of propargyl-allenyl type, they take part in cyclopropanations, rearrangements, cycloadditions, and electrocyclic processes.[22−26] They are valuable reagents for use in biological chemistry[27] found in naturally occurring products[28,29] and also included as a fragment into the structure of some anticancer drugs.[30] Despite a large number of methods for the synthesis of diazoketones published in the literature,[22,23,31−37] their applicability for the synthesis of heteroaroyl diazomethanes is extremely limited. All this makes us to conclude that the search for new safe and effective methods for the synthesis of both NH-1,2,3-triazoles and diazomethanes of the azoloyl series is an urgent task. To solve this dual problem at once, the reaction of enaminones of azole series 1 with arylsulfonyl azides 2, which could undergo, depending on the structure of reactants and reaction conditions, both competing reactions A and B (Scheme ) leading to NH-1,2,3-triazoles 4 and diazocarbonyl compounds 5, respectively, is particularly promising. It should be noted that no examples have been found in the literature when products of both types 4 and 5 were obtained and identified together in one reaction. Moreover, there is no information about the factors directing the conversion of triazolines 3 toward the formation of a particular product 4 or 5 (Scheme ) found by either experimental or computational methods. The reactions of sulfonyl azides 2 with heterocyclic enaminones 1 are presented in the literature to a much lesser extent than the corresponding reactions of aromatic[16,17,38,39] and alicyclic[38] enaminones. Thus, it is described[16] that the enaminones 1′a,b react with tosyl azide (2a) in water to form exclusively NH-triazoles 4′a,b (Scheme ), which are the only described examples of NH-1,2,3-triazoles linked with the second heterocycle through a carbonyl group.
Scheme 2

Synthesis of 4-Acyl-NH-1,2,3-triazoles and Azolyl Diazoketones

On the other hand, heterocyclic β-methylenaminones 1′c react with mesyl azide (2b) in water under microwave irradiation to form only the corresponding diazoketones 5′ (Scheme ).[40] The method of synthesis of heteroaroyl diazo compounds 7′ by the reaction of the corresponding chloroanhydrides 6′ with diazomethane (Arndt–Eistert synthesis) has not found a wide application[41−43] due to the high explosiveness and toxicity of the latter. Here, we demonstrate a new approach that allows one to obtain both NH-1,2,3-triazoles 4 and diazomethanes 5 of heteroaroyl series based on the use of either water-soluble sulfonyl azides or enaminones containing an N-methylpiperazine residue. This approach allowed us to develop a simple and effective method for separating the desired 4-acyl-NH-1,2,3-triazoles 4 and diazoketones 5 from byproducts, sulfonamides 6 and amidines 7 (Scheme ). A combination of experimental and computational studies of the interaction of azolylenaminones with sulfonyl azides revealed the influence of the nature of the starting reagents and the solvents on the direction of the reaction. It was found that seemingly insignificant changes in the structure of arylsulfonyl azide, as well as a variation like the solvent, lead to drastic changes in the direction of this reaction. It is shown that the reactions of the least electrophilic tosyl azide (2a) and 4-methoxyphenyl azide (2g) in pyridine lead to the selective formation of NH-1,2,3-triazoles 4. On the contrary, the formation of diazoketones 5 is facilitated by the use of azide 2e, containing a strong electron acceptor nitro group and ethanol as a solvent. Optimal conditions were determined, and methods were developed for the selective and effective synthesis of azoloyl NH-1,2,3-triazoles 4 and diazoketones 5.

Results and Discussion

As an enaminone substrate, we initially selected the earlier synthesized[44,45]N,N-dimethylenaminones 1a–o, as well as enaminone 1p [which we first obtained in two stages via 4-acetyl-1,2,3-triazole 9 from Zidovudine (8)] (Scheme ), where the substituent at position 1 of 1,2,3-triazole widely varied in electronic properties. In addition to 1,2,3-triazole derivatives 1a–p, one representative of the 1,2,3-thiadiazole 1q and isoxazole 1r(45) series were chosen for the study. Selected N,N-dimethylenaminones 1a–f,g–r were reacted with several sulfonyl azides R3SO2N3 (2) (R3 = 4-MeC6H4 (2a), Me (2b), Ph (2c), 4-F3CC6H4 (2d), and 4-O2NC6H4 (2e)).
Scheme 3

Scattered Examples of Reactions of Enaminones 1 with Sulfonyl Azides 2

As can be seen from Scheme , at the end of the synthesis, the reaction mixture generally contains four products, namely, two desired ones (4 and 5) and two byproducts (6 and 7). Often, non-stoichiometric ratios of reactants were used or their conversion turned out to be incomplete, which further complicates the reaction mixture due to residual amounts of reactants. The lack of differences in the components of the reaction mixture (including unpredictable chromatographic mobility), which would allow them to be easily separated, makes this task rather difficult. Indeed, in a series of experiments that we have carried out (Scheme ), complex combinations of chromatographic and other physico-chemical techniques had to be used to isolate the desired products of reaction 4, 5; in some cases, we could not isolate pure substances at all or only partially succeeded. We suggested that the cardinal solution of the problem could be the use of a radically different separation principle. To do this, we decided to introduce a basic fragment into the molecule of one of the reactants 1 or 2 and, consequently, into the byproducts 6 and 7, which gives the latter solubility in acidic aqueous medium. The acidity in reactants 1 or 2 as a factor in allowing the removal of byproducts 6 and 7 was not considered because one of the desired products, monosubstituted triazoles of type 4, are also quite strong acids that form stable salts with bases, for example, triethylamine. Initially, we decided to introduce a basic fragment into sulfonyl azide, which was achieved using the previously obtained[46] 2-morpholinoethane-1-sulfonyl azide (2f) (Scheme ).
Scheme 4

Scattered Reactions of Enaminones 1 with Azide 2f

The reactions were carried out in 1,4-dioxane and byproducts 6 and 7 were washed off after the removal of the solvent with an aqueous solution of AcOH (the use of strong acids is risky because their excess destroys diazo compounds 5). The easy removal of water-soluble byproducts 6 and 7 made it possible to obtain mixtures consisting predominantly of NH-triazoles 4 and diazo compounds 5, which allowed to analyze them without preparative separation using 1H NMR spectroscopy. The separation of the mixtures in order to obtain the components was carried out using column chromatography. Doing this, to increase the difference in the chromatographic mobility of NH-triazoles 4 and diazo compounds 5, the phenomenon of a pronounced acidity of the former was used. Thus, the addition of triethylamine to the eluent at the beginning of chromatography drastically reduced the R of NH-triazoles 4 due to the formation of a salt, as a result of which only diazo compounds 5 were eluted. Then, a small amount of AcOH was added to the eluent to destroy the salt, after which NH-triazoles 4 were eluted. However, in the majority of cases, the selective formation of one of the two types of reaction products does not take place (Scheme ). We assumed that the addition of acetic acid to the reaction mixture would shift the reaction in favor of the formation of diazo compounds 5 due to the neutralization of the basic morpholine fragment from sulfonyl azide 2f. Though the expected effect was observed in a series of experiments (cf. entry 4, Scheme , with entry 5 and, especially, entry 6), the desired selectivity was not achieved. Thus, the introduction of the basic fragment into the sulfonamide component of sulfonyl azides 2 did not provide the synthesis of NH-triazoles 4 and diazo compounds 5 with satisfactory selectivity, which reduces the preparative attractiveness of the tested approach. An approach alternative to the previous one is the use of enaminones of type 10 with the basic fragment of N-methylpiperazine, which was introduced instead of the dimethylamino group by the transamination reaction of enaminones 1. The preferred method for the synthesis of enaminones 10 was found to be heating enaminones 1 in N-methylpiperazine with letting the releasing dimethylamine to dissipate in the atmosphere (Scheme ). The excess N-methylpiperazine can be regenerated to a great extent by distilling it from the reaction mixture after the end of the reaction. Thus, a series of new enaminones bearing a fragment of N-methylpiperazine of the 1,2,3-triazole series 10a–p was obtained, as well as one representative of the 1,2,3-thiadiazole 10q and isoxazole 10r series (Scheme ).
Scheme 5

Syntheses of N-Methylpiperazine Enaminones 10

In the synthesis of the o- (10c) and p-nitro derivative (10d), significant amounts of o- and p-nitroaniline were detected in the reaction mixture, respectively, presumably due to the decomposition of compounds 10c and 10d under the action of N-methylpiperazine. As a result, p-nitro enaminone 10d was obtained with a yield of 82%, and the yield of o-isomer 10c was only 48% with a conversion rate of the starting compound 1c of 95%. Thus, the transamination reaction is of limited applicability for the preparation of compounds 10 that are labile to N-methylpiperazine. The synthesized enaminones 10 have a higher melting point, are more stable during storage and are significantly more polar than initial dimethyl enaminones 1, which favor their purification by crystallization or column chromatography, and altogether make them more convenient in synthetic practice. In syntheses using N-methylpiperazine enaminones 10 (Scheme ), it was found possible to apply a method for isolating compounds 4 and 5, similar to the one used in the reaction of enaminones 1 with azide 2f (Scheme ).
Scheme 6

Reactions of N-Methylpiperazine Enaminones 10 with Sulfonyl Azides 2

In order to increase the practical value of the method under development, we looked for the reaction conditions leading to the predominant formation of one of the two types of reaction products, NH-triazoles 4 or diazo compound 5. Initially, the influence of the nature of sulfonyl azide 2 on the ratio of reaction products when interacting with enaminone 10h (Scheme ) was studied. The reactions were carried out in 1,4-dioxane at room temperature.
Scheme 7

Reaction of Enaminone 10h with Sulfonyl Azides 2a–e and 2g in 1,4-Dioxane

Based on the experimental results presented in Scheme , it can be concluded that the electronic properties of the substituent in sulfonyl azides 2 significantly affect the direction of the reaction. Thus, the use of azides 2a and 2g containing electron-donating substituents leads to a maximum yield of NH-triazole 4h (Scheme , entries 1 and 6), while sulfonyl azide 2e with an electron-acceptor group affords the maximum yield of diazo compound 5h (Scheme , entries 1, 6). For the further optimization of the method for obtaining NH-triazoles 4 from a pair of arylsulfonyl azides 2a and 2g, which showed similar results, tosyl azide (2a) was chosen as much more available. Thus the study of the effect of the solvent nature on the yield of NH-triazoles 4 (Scheme ) was carried out using the reaction of enaminone 10h with tosyl azide (2a).
Scheme 8

Reaction of Enaminone 10h with Azide 2a in Different Solvents

Data of Scheme demonstrate that the best yields of NH-triazole 4h are provided by the use of pyridine as a solvent (entries 9–11). Further, the effect of the reaction temperature on the yield of the desired NH-triazole 4h was studied in this solvent (Scheme , entries 9–11). Notably, an increase in temperature to 75 °C leads to a certain decrease in the yield of the desired product 4h (Scheme , entry 11), while it is practically invariable in the temperature range from room to 52 °C. It should be noted that in the studies presented in Schemes and 8, an attempt to introduce into the reaction an excess of enaminone 10h or sulfonyl azide 2 always led only to that after the reactant taken in deficiency completely disappeared, the reactant taken in excess was detected in the reaction mixture using 1H NMR, moreover in an amount close to that expected by balance calculation, while the yield of the desired products 4 and 5 remained practically the same. Thus, the optimal conditions for the synthesis of NH-triazoles 4 from enaminones 10 were recognized as the use of tosyl azide (2a) as a sulfonyl azide and pyridine as a solvent at a temperature of 25–52 °C with an equimolar ratio of reactants. Having optimal conditions in hands, we synthesized a series of compounds of the 1,2,3-triazole series 4a–p, as well as one representative of the 1,2,3-thiadiazole 4q and isoxazole 4r series; the results are given in Scheme .
Scheme 9

Syntheses of NH-Triazoles 4a–r in Optimized Conditions

As already noted, the highest yield of diazo compound 5h in the experiments presented in Scheme is achieved using 4-nitrophenylsulfonyl azide (2e). In this respect, the optimization of the method for obtaining diazo compounds 5 was carried out using reagent 2e. Thus, the effect of the solvent on the yield of reaction products was studied by analyzing a series of experiments, where it changed in the reaction of sulfonyl azide 2e with enaminone 10q. It was found that in this series (entries 1–5, Scheme ), the use of ethanol leads to the maximum yield of diazo compound 5q. Later, we locked ethanol as a solvent and investigated the effect of the reaction temperature on the yield of diazo compound 5q (entries 5–7, Scheme ). It was revealed that the yield of diazo compound 5q decreased in the row rt > 4 °C ≈ 70 °C.
Scheme 10

Reaction of Enaminone 10q with Azide 2e in Different Solvents

Similar to the optimization of the synthesis of NH-triazoles 4 (Schemes and 10), the use of an excess of enaminone 10q or sulfonyl azide 2e in the reaction led merely to their overspending. As a result, the best conditions for the synthesis of diazo compounds 5 from enaminones 10 were formulated as follows: 4-nitrophenylsulfonyl azide (2e) as a sulfonyl azide, ethanol, or methanol as a solvent, the reaction temperature was room temperature (in the case of enaminone 10o, the reaction was carried out at an elevated temperature because of its low solubility) with an equimolar ratio of reactants. In these optimal conditions, a series of diazocarbonyl compounds of 1,2,3-triazole 5a–p series were synthesized, as well as one representative of 1,2,3-thiadiazole 5q and isoxazole 5r series, which are given in Scheme .
Scheme 11

Syntheses of Diazo Compounds 5a–r in Optimized Conditions

NH-1,2,3-Triazoles 4 are solid colorless substances with a relatively high melting point. Their structure correlates with the data of 1H and 13C NMR spectroscopy, which was also confirmed by ultra-high-performance liquid chromatography with high-resolution mass spectrometry (UHPLC-HRMS) detection, and X-ray analysis was performed for a single crystal of compound 4f (Figure ).
Figure 1

Molecular structure of NH-triazole 4f solvate with a representation of the atoms by thermal vibration ellipsoids of 50% probability.

Molecular structure of NH-triazole 4f solvate with a representation of the atoms by thermal vibration ellipsoids of 50% probability. Diazo compounds 5 are solid light yellow substances with a relatively low melting point (n-butyl derivative 5f could not be crystallized). Their structure correlates with the data of 1H and 13C NMR spectroscopy and UHPLC-HRMS. In the 1H NMR spectra of diazo compounds 5, broad singlets of protons from the diazoketone fragment C(=O)CHN2 are observed at 5.04–6.76 ppm. The IR spectra of compounds 5 display the characteristic bands of the valence vibrations of the diazo group in the range of 2096–2115 cm–1. Additionally, the structure of diazo compounds 5 is confirmed by the X-ray analysis performed for a single crystal of compound 5c (Figure ).
Figure 2

Molecular structure of compound 5c with representation of the atoms by thermal vibration ellipsoids of 50% probability.

Molecular structure of compound 5c with representation of the atoms by thermal vibration ellipsoids of 50% probability. Previously, the synthesis of one of the diazo compounds, 2-diazo-1-(5-methyl-1,2,3-thiadiazol-4-yl)methyl-1-one (5q), by an alternative method is described in ref (42). However, except for the melting point, no analytical characteristics are published in the article,[42] which makes it unsuitable for confirmation of the structure of compound 5q synthesized by us. The plausible mechanism for the formation of compounds 5–7 is depicted in Scheme . We assumed that triazoline 3 generated by the cycloaddition reaction of enaminone 1 with sulfonyl azide 2 is a common intermediate on pathways A and B, leading to the desired products 4 and 5. Theoretically, as indicated in Scheme , pathway A includes the elimination of sulfonyl amide 6 and formation of triazoline 11, which is followed by the 1,3-H shift to result in final NH-triazole 5 (A1) or via the elimination of dialkyl amine and generation of 1-arylsulfonyl-1,2,3-triazole 12. The latter reacts with dialkyl amine to form triazole 5 accompanied by sulfonamide 4 (A2). We also assume that the formation of the second desired compound, diazo compound 5, occurs via the cycloreversion of triazoline 3.[21] Therefore, we have performed computational simulations to gain close insights into the nature of such an important transformation using density functional theory (DFT) approaches (see below).
Scheme 12

Plausible Mechanism of Formation of NH-Triazoles 4 and Diazo Compounds 5

Computational Investigations

We next performed DFT simulations to gain further insights into the reaction mechanism. The calculations were performed at the (SMD)-M06-2X/6-311+G(d,p)//M06-2X/6-31G(d) level of theory (see the Computational Methods). Overall, we have calculated the mechanistic pathway for the formation of the desired product 4a and its isomers in 1,4-dioxane (Figure ). Despite the cycloaddition of enaminone 1a with sulfonyl azide 2a being approximately thermoneutral to give intermediate Int4a, the latter is kinetically favored over by a substantial barrier difference of more than 16 kcal/mol via TS3a although the other isomeric intermediate Int4a is slightly thermodynamically exergonic (ΔG = −2.1 kcal/mol). This sharp preferability for the formation of intermediate Int4a is reasoned to factors indicated below.
Figure 3

Computational evaluation of the reaction mechanism for the formation of NH-1,2,3-triazoles 4a (black pathway) and its isomer 13 (blue pathway) calculated at the (SMD)-M06-2X/6-311+G(d,p)//M06-2X/6-31G(d) level of theory at 298.15 K in 1,4-dioxane, showing important selected transition-state geometries.

Computational evaluation of the reaction mechanism for the formation of NH-1,2,3-triazoles 4a (black pathway) and its isomer 13 (blue pathway) calculated at the (SMD)-M06-2X/6-311+G(d,p)//M06-2X/6-31G(d) level of theory at 298.15 K in 1,4-dioxane, showing important selected transition-state geometries. This regiomeric preferability of the formation of intermediate Int4a has shown to be important to rationalize the considerable difference between TSs leading to different regioisomers. Generally, the 1,3-dipolar cycloaddition is a concerted and pericyclic process as an asynchronous addition, where both electronic[47,48] and steric factors[49,50] significantly contributed to the regioselectivity. The electronic effect is a dominant combination of the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO), and this is clearly governed by the largest coefficients of HOMO and LUMO of the reacting atoms. Although the steric effect is well known to compete with the electronic effects through favoring the opposite regioisomer exclusively, we have noticed a remarkably different behavior here that would lead to a considerable energy difference between TS3a and TS3a. Our simulations have revealed three important observations that make TS3a considerably more favorable than TS3a (Figure a). First, the non-covalent interaction (NCI) calculations disclose a strong bonding interaction between methyl groups of enaminone and oxygen atoms of sulfonyl azide, as shown by the absolute values of charges for atom H20 with O30 and atom H23 with O31 (Figure a). Second, and in this regard, the NCI results manifest an electrostatic interaction between the hydrogen atom H5 of the triazole ring and the nitrogen atom N28 of the azide moiety. These two types of interactions are completely absent in the other TS, TS3a. Third, the high asynchronous attack via (3 + 2) cycloaddition is clearly evidenced (Figure b). The intrinsic reaction coordinate (IRC) calculations showed that while the first N–C bond forms at 1.56 Å, the other N–C bond is still away in the transition state zone at 2.37 Å, consequently resulting in a high asynchronous (3 + 2) cycloaddition due to a 0.81 Å bond difference between the first and second N–C bond formation (Figure b, top). However, the other regiomeric (3 + 2) addition through TS3a is calculated to be totally concerted, as indicated by the IRC calculations, by which the formation of both N–C bonds reaches 1.56 Å simultaneously (Figure b, bottom).
Figure 4

(a) Optimized geometry of TS3a; selected charges and bond lengths (top) with its NCI plot indicating important non-covalent interactions are shown (bottom). (b) Minimum energy path diagrams for the (3 + 2) cycloaddition of alkene 1a and sulfonyl azide 2a determined by performing M06-2x/6-31G (d) IRC calculations for TS3a and TS3a, showing a plot of the relative electronic energy along with mass-weighted reaction coordinate s (amu1/2 Å). (c) Effect of substituents on computed free energies of activations and reactions (in kcal/mol) for the formation of intermediate Int4a via TS3a calculated at the (SMD)-M06-2X/6-311+G(d,p)//M06-2X/6-31G(d) level of theory at 298.15 K in 1,4-dioxane.

(a) Optimized geometry of TS3a; selected charges and bond lengths (top) with its NCI plot indicating important non-covalent interactions are shown (bottom). (b) Minimum energy path diagrams for the (3 + 2) cycloaddition of alkene 1a and sulfonyl azide 2a determined by performing M06-2x/6-31G (d) IRC calculations for TS3a and TS3a, showing a plot of the relative electronic energy along with mass-weighted reaction coordinate s (amu1/2 Å). (c) Effect of substituents on computed free energies of activations and reactions (in kcal/mol) for the formation of intermediate Int4a via TS3a calculated at the (SMD)-M06-2X/6-311+G(d,p)//M06-2X/6-31G(d) level of theory at 298.15 K in 1,4-dioxane. Despite the fact that the 1,3-dipolar cycloaddition reaction was previously investigated using DFT simulations,[51−53] our novel (3 + 2) cycloaddition seems to be in need for further attention. The effect of substituents on the 1,3-dipolar cycloaddition is investigated and shown in Figure c. In this regard, in comparison with our model investigated here, R1 and R2 = Me (Figure c, entry 1), replacing the methyl group with a phenyl group results in the formation of a five-membered ring with a slightly less barrier of ΔΔG⧧ = 0.4 kcal/mol, making it slightly more exergonic (ΔΔGr = −1.3 kcal/mol) (Figure c, entry 2). While R2 remains a Ph group and R1 is substituted with methyl at the para position, the calculated barrier increases to 25.5 kcal/mol but becomes more exergonic (ΔGr = −2.9 kcal/mol) (Figure c, entry 3). In contrast, the barrier dropped to 24.8 kcal/mol when a para-methyl group was replaced with a para-nitrophenyl group (Figure c, entry 4). Interestingly, in the presence of an electron-withdrawing group like NO2 in sulfonyl azide (R2), when R1 = Ph, the five-membered ring formation proceeded with a reduced barrier of 23.3 kcal/mol (Figure c, entry 6) compared to our model substrate used in this investigation (Figure c, entry 1, R1, R2 = Me). Overall, from these results, the rate of cycloaddition seems to be more likely higher when the electron-deficient group is involved in the azide moiety. To complete the pathway of NH-1,2,3-triazoles 8a formation, we assumed that favorable intermediate Inta4 would undergo two separate pathways to release three different molecules (8, Int11, and 13), as shown in Figure . On the one hand, intermediate Int4a affords the elimination of sulfonyl amide 9 and triazoline Int11, which follows by either 1,3-H shift to form NH-triazole 13 or 1,2-H shift to form our desired product 8. However, this pathway was shown to be kinetically disallowed due to the substantial barrier of 37.8 kcal/mol that is needed to be overcome via TS10 as a thermoneutral step (ΔG = −0.8 kcal/mol) to give intermediate Int11. Concurrently, in addition to the unfavorable sulfonyl amide 9 elimination, the intermediate Int11 will subsequently undergo either a high activation barrier of 25.7 kcal/mol via 1,2-H shift TS12 to furnish compound 13 or through a forbidden pathway 1,3-H shift TS12 with a barrier of 59.3 kcal/mol to release compound 8. Therefore, regarding the mild conditions employed in our methodology, both shifts were totally ruled out. On the other hand, the elimination of dimethyl amine and generation of 1-methylsulfonyl-1,2,3-triazole intermediate Int6a seems to be a more sensible pathway although it still required a higher barrier of 29.7 kcal/mol through the four-membered transition-state TS5a as a highly exergonic step of 16.8 kcal/mol to form intermediate Int6a (Figure ). If latter intermediate Int6a is formed, it reacts with dimethylamine to form triazole 8a accompanied with sulfonyl amide 9 with a calculated exergonicity of 17.0 kcal/mol. Therefore, to overcome this high calculated barrier via TS5a and allow a smooth dimethyl amine elimination, a water molecule is needed to form a six-membered TS. Indeed, the addition of a water molecule as a catalyst lowers the barrier of HNMe2 elimination to 23.8 kcal/mol within a relaxed TS TS5a rather than 29.7 kcal/mol with a strained TS within TS5a. Therefore, according to the calculations performed for the model reaction of 1-(1,5-dimethyl-1H-1,2,3-triazol-4-yl)-3-(dimethylamino)prop-2-en-1-one (1a) with mesyl azide (2a), the dialkyl amine elimination is more preferable by more than 13 kcal/mol than sulfonyl amide elimination. Further DFT simulations were performed to understand the formation of diazo compound 5a under these reaction conditions. We assume that the formation of the second desired compound occurs via the (3 + 2) cycloreversion of triazoline intermediate Int4a. Figure shows an energetic comparison between the elimination and cycloreversion of intermediate Int4a calculated in 1,4-dioxane. The results presented in Figure indicate that the elimination pathway is more favored than cycloreversion. Here, the cycloreversion needs a further higher barrier of 28.6 kcal/mol to release diazo compound 5a as a less exergonic pathway of 7.6 kcal/mol. Based on the experimental observations, we have seen that switching solvents from 1,4-dioxane to ethanol tunes the reaction direction in favor of diazo compound 5a formation. Accordingly, we have performed our simulations in ethanol to reveal the impact of the solvent on the pathway preferability.
Figure 5

Free energy profile for the elimination and cycloreversion of cyclic intermediate Int4a calculated in 1,4-dioxane at the (SMD)-M06-2X/6-311+G(d,p)//M06-2X/6-31G(d) level of theory at 298.15 K.

Free energy profile for the elimination and cycloreversion of cyclic intermediate Int4a calculated in 1,4-dioxane at the (SMD)-M06-2X/6-311+G(d,p)//M06-2X/6-31G(d) level of theory at 298.15 K. Table presents the effect of the solvent (1,4-dioxane and ethanol) and substituents on computed free energy of activation for the elimination and cycloreversion pathways from triazoline intermediate Int4. Overall, the results point out that elimination is more likely to be favored in 1,4-dioxane despite the variety of substituents, whereas the cycloreversion comparatively becomes clearly favorable than elimination in ethanol. More importantly, our calculations reveal that 1,4-dioxane lowers the barrier needed for the elimination process, whereas ethanol increases the barrier dramatically. Conversely, 1,4-dioxane increases the barrier of cycloreversion largely, whereas ethanol decreases the barrier of cycloreversion substantially. According to our calculations, the barrier for the cycloreversion of intermediate Int4 is substantially lower in ethanol for the azide moiety with electron-withdrawing R2 = 4-O2N (Table , entry 6). Finally, these results indicate that the solvent is paramount in terms of directing the pathway of intermediate Int4 toward cycloreversion or elimination.
Table 1

Computed Free Energy of Activation (in kcal/mol) Showing the Effect of Substituents on the Cycloreversion Step of Intermediate Int4 through TS15a-F and Compared with Elimination through TS5a-F Calculated at the (SMD)-M06-2X/6-311+G(d,p)//M06-2X/6-31G(d) Level of Theory in Two Different Solvents 1,4-Dioxane and Ethanol at 298.15 K

   elimination TS5H2Oa–f (ΔG)
cycloreversion TS15a–f (ΔG)
entryR1R21,4-dioxaneethanol1,4-dioxaneethanol
1MeMe23.827.828.625.2
2PhPh26.127.726.122.7
34-MeC6H4Ph26.227.726.322.1
44-O2NC6H4Ph26.228.126.823.2
5Ph4-MeC6H425.825.924.920.3
6Ph4-O2NC6H422.124.321.816.9

Conclusions

In conclusion, the interaction of azolyl enaminones 1 with sulfonyl azides 2 was studied. Examples of the concurrent formation of two types of products, NH-1,2,3-triazoles 4 and azolyl diazoketones 5, were discovered. The introduction of the basic fragment into the molecule of one of the reactants made it possible to significantly simplify the technology of isolating the desired products. By varying the sulfonyl azide, solvent, and reaction temperatures, factors favoring the implementation of each of the alternative pathways were found, and convenient laboratory methods for the synthesis of several hitherto unavailable azolyl-4-carbonyl-NH-1,2,3-triazoles 4 as well as azolyl diazoketones 5 were developed. DFT calculations were utilized to reveal the mechanism of the formation of NH-triazoles from enaminone 1a and azide 2a. The DFT results have shown that the 1,3-dipolar cycloaddition is totally driven toward one single regioisomer with a high asynchronous bond formation with non-covalent interactions being considerably effective, by which the existence of an electron-deficient group on sulfonyl azides induces faster cycloaddition. Following the formation of the cycloadduct intermediate, namely, 4H-1,2,3-triazole, the reaction was found to undergo smoothly within the six-membered TS elimination of dialkyl amine, facilitated by a water molecule, which undergoes an N–S bond cleavage to release the desired product 4a. In this regard, our calculations revealed that 1,4-dioxane makes the elimination process more favorable, whereas cycloreversion becomes the preferred pathway to form diazo compound 5a when ethanol is used. Finally, this work opens an avenue to the selective convenient preparation (including scale-up production) of diverse NH-1,2,3-triazoles and carbonyldiazomethanes, valuable as building blocks and for the other applications.

Experimental Section

General

1H, 13C, and 19F NMR spectra were recorded at 400 and 600 MHz (1H), 101 and 151 MHz (13C), and 376 MHz (19F) in DMSO-d6a or DCCl3 solutions. Unless specifically mentioned, 13C NMR spectra were recorded with proton decoupling (BB); spectra of diazo compounds 5n,o were obtained in the J-mode (attached proton test, APT). For NMR spectra on 1H and 13C nuclei, the residual signals DMSO-d5 and HCCl3 were used as an internal reference. In the 19F NMR spectra, the chemical shifts of the signals are given relative to FCCl3. The analysis of compounds by UHPLC-HRMS was performed using a tandem quadrupole time-of-flight accurate mass detector, chromatographic separation was achieved using an ultra-high-performance liquid chromatography. The preliminary control of the progress of reactions and the purity of the obtained products was carried out on plates for TLC “Sorbfil” UV-254, manifestation in UV light. The temperatures of the reactions are indicated in the bath. For column chromatography, KSKG silica gel of a fraction of 40–100 μm was used. All reactions, except for the specially indicated cases, were carried out in sealed vessels. The evaporation of volatile components and concentration of solutions were performed at reduced pressure. The separation of the solid phase from the liquid was carried out by centrifugation (3000 rpm). Melting points were determined on a melting point apparatus and are uncorrected. All solvents were prepared according to standard methods, a petroleum ether (PE) fraction of 70–100 °C was used.

Starting Materials

The synthesis of N,N-dimethylenaminones 1a–o,q,r was described earlier.[44,45] Sulfonyl azides 2a–c,e were prepared from the corresponding sulfonyl chlorides.[54] Compound 2d was obtained according to ref (55). Water-soluble sulfonyl azide 2f was synthesized as is described in ref (46). Substance Zidovudine 8 is commercially available.

1-((2R,5S)-4-(4-Acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (9)

A solution of Zidovudine (8) (1030 mg, 3.85 mmol), acetylacetone (1517 mg, 15.15 mmol), Et3N (780 mg, 7.71 mmol), and DBU (253 mg, 1.66 mmol) in 1,4-dioxane (2.1 g) was kept at 55 °C for 3 d. Volatiles were evaporated to dryness, the residue was treated with PE. The residue was separated with column chromatography: applied as a solution in DCM, eluted successively with DCM and DCM/EtOAc (1:1), and finally with EtOAc. Portions of the EtOAc eluate, containing the desired product, were combined, evaporated to dryness, and the residue was crystallized from EtOH, washed with Et2O, and dried. Yield 32% (722 mg), beige powder, mp 165–169 °C. 1H NMR (400 MHz, DMSO-d6): δ 1.81 (s, 3H), 2.57 (s, 6H), 2.63–2.68 (m, 1H), 2.70–2.82 (m, 1H), 3.63–3.70 (m, 2H), 4.26 (d, J = 3.6 Hz, 1H), 5.21 (t, J = 4.0, Hz, 1H), 5.31 (t, J = 4.8 Hz), 6.50 (t, J = 6.8 Hz, 1H), 7.79 (s, 1H), 11.34 (s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 8.7, 12.3, 27.5, 36.8, 57.4, 61.0, 61.06, 84.4, 109.8, 136.1, 137.5, 142.8, 150.5, 163.7, 193.4. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C15H20N5O5, 350.1459; found, 350.1468.

1-((2R,5S)-4-(4-((E)-3-(Dimethylamino)acryloyl)-5-methyl-1H-1,2,3-triazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,5-dimethylpyrimidine-2,4(1H,3H)-dione (1p)

A solution of acetyl derivative 9 (455 mg, 1.30 mmol) in DMF–DMA (10 g) was refluxed for 22 h. Volatiles were evaporated to dryness. The residue was purified with column chromatography: applied as a solution in DCM, eluted successively with DCM and EtOAc, and finally with EtOAc/MeOH (1:1). Portions of the EtOAc/MeOH eluate, containing the desired product 1p, were combined, evaporated to dryness, crystallized from EtOH, washed with Et2O, and dried. Yield 88% (478 mg). Light yellow powder, mp 215–220 °C. 1H NMR (400 MHz, DCCl3): δ 1.93 (s, 3H), 2.64 (s, 3H), 2.94 (s, 3H), 2.97 (dd, J = 6.4, 4.3 Hz, 1H), 3.14 (s, 3H), 3.33 (s, 3H), 3.67 (d, J = 12.3 Hz, 1H), 4.00 (d, J = 12.4 Hz, 1H), 4.48 (d, J = 4.9 Hz, 1H), 5.29 (dd, J = 13.3, 5.9 Hz, 1H), 6.16 (d, J = 12.3 Hz, 1H), 6.25 (t, J = 6.5 Hz, 1H), 7.40 (s, 1H), 7.80 (d, J = 12.3 Hz, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 9.2, 13.3, 27.9, 37.4, 45.2, 55.9, 61.6, 85.3, 90.1, 93.5, 110.3, 136.0, 136.1, 144.7, 151.1, 153.8, 163.6, 182.5. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C19H27N6O5, 419.2037; found, 419.2056.

General Procedure for the Preparation of Enaminones 10

A mixture of enaminone 1 (3.0 mmol) and N-methylpiperazine (4 mL) was refluxed with communication with the atmosphere for 2 min–5 h. For compounds, 10a–c, 10h, 10l, and 10q, an excess of N-methylpiperazine was distilled off. For compounds 10d, 10p, and 10s, thick suspensions were formed and distillation of excessive N-methylpiperazine was done after the removal of the solid phase. The distillate (2.0–2.6 mL or 50–65%) was recovered and used in the further syntheses. For more information about product isolation, see each specific case.

(E)-3-(4-Methylpiperazin-1-yl)-1-(1-phenyl-1H-1,2,3-triazol-4-yl)prop-2-en-1-one (10a)

Compound 10a was obtained in 80% (714 mg) yield according to the general procedure (enaminone 1a: 727 mg, 5 h). The crude product was purified with column chromatography: applied as a solution in EtOAc, eluted successively with EtOAc and EtOAc/EtOH (10:1), and finally with EtOAc/EtOH (5:1). The last portions of the eluate, containing enaminone 10a, were combined, evaporated to dryness, and the residue was crystallized from PhH/PE. Light yellow powder, mp 143–146 °C. 1H NMR (400 MHz, DCCl3): δ 2.30 (s, 3H), 2.38–2.50 (m, 4H), 3.38–3.52 (m, 4H), 6.30 (d, J = 12.5 Hz, 1H), 7.42 (d, J = 7.3 Hz, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.73 (d, J = 7.7 Hz, 2H), 7.86 (d, J = 12.5 Hz, 1H), 8.47 (s, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 45.4, 46.1, 53.4, 53.8, 55.0, 92.8, 120.6, 123.0, 129.1, 129.9, 136.9, 150.4, 152.6, 181.0. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C16H20N5O, 298.1662; found, 298.1674.

(E)-3-(4-Methylpiperazin-1-yl)-1-(1-(p-tolyl)-1H-1,2,3-triazol-4-yl)prop-2-en-1-one (10b)

Compound 10b was obtained in 98% (916 mg) yield according to the general procedure (enaminone 1b: 769 mg, 5 h). The crude product was purified with column chromatography: applied as a solution in EtOAc, eluted successively with EtOAc and EtOH, and finally with EtOH with the addition of Et3N (5 drops per 10 mL). Portions of the eluate (EtOH/Et3N), containing enaminone 10b, were combined, evaporated to dryness, and crystallized from PhH–PE. Light yellow powder, mp 174–176 °C. 1H NMR (400 MHz, DCCl3): δ 2.31 (s, 3H), 2.40 (s, 3H), 2.45 (dd, J = 13.1, 8.0 Hz, 4H), 3.37–3.53 (m, 4H), 6.31 (d, J = 12.5 Hz, 1H), 7.30 (d, J = 8.3 Hz, 2H), 7.61 (d, J = 8.4 Hz, 2H), 7.87 (d, J = 12.5 Hz, 1H), 8.43 (s, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 21.1, 45.3, 46.0, 53.2, 53.8, 54.9, 92.7, 120.4, 122.9, 130.3, 134.5, 139.1, 150.2, 152.5, 181.0. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C17H22N5O, 312.1819; found, 312.1833.

(E)-3-(4-Methylpiperazin-1-yl)-1-(1-(2-nitrophenyl)-1H-1,2,3-triazol-4-yl)prop-2-en-1-one (10c)

Compound 10c was obtained in 48% (493 mg) yield according to the general procedure (enaminone 1c: 862 mg, 2.5 h). The crude product was purified with column chromatography: applied as a solution in EtOAc, eluted successively with EtOAc and EtOAc with the addition of Et3N (5 drops per 10 mL), and finally with EtOAc/EtOH (1:1) with the addition of Et3N (5 drops per 10 mL). Portions of the eluate (EtOAc/EtOH/Et3N), containing enaminone 10c, were combined, evaporated to dryness, and crystallized from PhH–PE. Yellow powder, mp 165–167 °C (decomp.). 1H NMR (400 MHz, DCCl3): δ 2.32 (s, 3H), 2.40–2.56 (m, 4H), 3.36–3.56 (m, 4H), 6.29 (d, J = 12.4 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.71 (dd, J = 11.2, 4.3 Hz, 1H), 7.79 (dd, J = 11.2, 4.3 Hz, 1H), 7.89 (d, J = 12.4 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 8.34 (s, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 45.4, 46.1, 53.4, 53.8, 55.1, 92.8, 125.8, 126.5, 127.8, 130.1, 131.1, 134.0, 144.5, 150.3, 152.7, 180.5. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C16H19N6O3, 343.1513; found, 343.1519.

(E)-3-(4-Methylpiperazin-1-yl)-1-(1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)prop-2-en-1-one (10d)

Compound 10d was obtained in 82% (842 mg) yield according to the general procedure (enaminone 1d: 862 mg, 1 h; DMF for better solubility: 2 mL). The crude product was washed with EtOH and twice with Et2O. The residue was crystallized from 1,4-dioxane. Yellow powder, mp >240 °C (decomp.). 1H NMR (400 MHz, DMSO-d6): δ 2.33 (s, 3H), 2.61 (s, 2H), 3.41 (s, 2H), 3.47–3.79 (m, 4H), 6.25 (d, J = 12.6 Hz, 1H), 7.92 (d, J = 12.6 Hz, 1H), 8.40 (d, J = 8.7 Hz, 2H), 8.55 (d, J = 8.7 Hz, 2H), 9.53 (s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 45.5, 54.0, 66.4, 92.0, 121.0, 124.4, 125.4, 140.7, 147.0, 150.1, 152.3, 178.7. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C16H19N6O3, 343.1513; found, 343.1525.

(E)-1-(1,5-Dimethyl-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10e)

Compound 10e was obtained in 95% (711 mg) yield according to the general procedure (enaminone 1e: 583 mg, 20 min). The crude product was treated with boiling n-octane. The residue was crystallized from PhH–PE to afford pure enaminone 10e. Light yellow powder, mp 171–174 °C. 1H NMR (400 MHz, DCCl3): δ 2.29 (s, 3H), 2.36–2.49 (m, 4H), 2.58 (s, 3H), 3.27–3.52 (m, 4H), 3.92 (s, 3H), 6.29 (d, J = 12.9 Hz, 1H), 7.71 (d, J = 12.9 Hz, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 9.1, 34.1, 45.3, 46.1, 53.0, 54.3, 93.4, 135.9, 144.5, 151.7, 183.2. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H20N5O, 250.1662; found, 250.1670.

(E)-1-(1-Butyl-5-methyl-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10f)

Compound 10f was obtained in 90% (787 mg) yield according to the general procedure (enaminone 1f: 709 mg, 5 min). The crude product was purified with column chromatography: applied as a solution in DCM and eluted successively with DCM and DCM with the addition of Et3N (5 drops per 10 mL). Portions of eluate containing enaminone 10f, were combined, evaporated to dryness, and crystallized from PE. Light yellow powder, mp 74–76 °C. 1H NMR (400 MHz, DCCl3): δ 0.93 (t, J = 7.4 Hz, 3H), 1.32 (dd, J = 15.1, 7.5 Hz, 2H), 1.67–1.92 (m, 2H), 2.28 (s, 3H), 2.42 (t, J = 4.0 Hz, 4H), 2.57 (s, 3H), 3.32–3.57 (m, 4H), 4.21 (t, J = 7.3 Hz, 2H), 6.30 (d, J = 12.9 Hz, 1H), 7.70 (d, J = 12.9 Hz, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 9.1, 13.5, 19.7, 31.7, 45.3, 46.1, 47.2, 52.9, 54.4, 93.5, 135.3, 144.3, 151.6, 183.3. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C15H26N5O, 292.2132; found, 292.2137.

(E)-1-(1-(4-Bromobenzyl)-5-methyl-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10g)

Compound 10g was obtained in 98% (1189 mg) yield according to the general procedure (enaminone 1g: 1213 mg, 5 min). The crude product was purified with column chromatography: applied as a solution in DCM, eluted successively with DCM and EtOAc, and finally with DCM with the addition of Et3N (5 drops per 10 mL). Portions of the eluate, containing enaminone 10g, were combined, evaporated to dryness, and crystallized from PhH–PE. Colorless powder. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C18H23BrN5O, 404.108; found, 404.1086. The structure of compound 10g favors the trapping of residual solvents, which are difficult to get rid off. For the spectral confirmation of the structure, picrate adduct 10ga was prepared.

(E)-1-(1-(4-Bromobenzyl)-5-methyl-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one Picrate (10ga)

To a mixture of enaminone 10g (100 mg, 0.286 mmol) in EtOH (900 mg), a solution of picric acid (66 mg, 0.286 mmol) in EtOH (400 mg) was added at vigorous stirring. A thick yellow solid phase forms immediately. After stirring for 5 min, the solid phase was separated and washed once with a small amount of EtOH and with Et2O (twice). The crude product was crystallized from AcMe–Et2O to obtain analytically pure compound 10ga in 73% (120 mg) yield. Yellow powder, mp 179–182 °C. 1H NMR (600 MHz, DMSO-d6): δ 2.47 (s, 3H), 2.85 (s, 3H), 3.12 (br s, 2H), 3.47 (br s, 4H), 3.95 (br s, 2H), 5.60 (s, 2H), 6.30 (d, J = 13.1 Hz, 1H), 7.14 (d, J = 8.5 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 13.1 Hz, 1H), 8.59 (s, 2H), 9.67 (s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 46.3, 79.9, 87.3, 87.5, 89.6, 131.9, 158.9, 161.9, 162.9, 167.2, 169.4, 172.4, 173.6, 179.5, 181.4, 188.7, 198.5, 219.5.

(E)-1-(5-Methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10h)

Compound 10h was obtained in 96% (897 mg) yield according to the general procedure (enaminone 1h: 769 mg, 2 h). The crude product was treated with hot PE at stirring. The mixture was left to cool to room temperature, the solid phase was separated, washed with PE, and dried. Light gray powder, mp 170–172 °C. 1H NMR (400 MHz, DCCl3): δ 2.30 (s, 3H), 2.37–2.52 (m, 4H), 2.60 (s, 3H), 3.35–3.54 (m, 4H), 6.39 (d, J = 12.8 Hz, 1H), 7.43 (d, J = 7.0 Hz, 2H), 7.52 (d, J = 7.5 Hz, 3H), 7.76 (d, J = 12.8 Hz, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 10.2, 45.8, 46.1, 53.1, 54.4, 93.6, 125.3, 129.5, 129.6, 135.9, 136.3, 144.5, 151.7, 183.1. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C17H22N5O, 312.1819; found, 312.1828.

(E)-1-(5-Methyl-1-(p-tolyl)-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10i)

Compound 10i was obtained in 93% (912 mg) yield according to the general procedure (enaminone 1i: 811 mg, N-methylpiperazine 2.6 g, 5 min). The reaction mixture was cooled to room temperature, the thick solid phase was separated, and washed with Et2O twice. Crude enaminone 10i was crystallized from PhH–PE to afford pure compound 10i. To obtain the additional amount of enaminone 10i, the filtrate from the crystallization was evaporated to dryness. The filtrate from the reaction mixture and Et2O washes were combined, excess of N-methylpiperazine was recovered by evaporation, and the solid residue was treated with PE three times. Both residues were combined and purified with column chromatography: applied as a solution in DCM, eluted successively with DCM and EtOAc, and finally with EtOAc/EtOH (1:1). Portions, containing the product 10i, were combined, evaporated to dryness, and crystallized from PhH–PE to afford the additional amount of pure enaminone 10i. Light yellow powder, mp 190–192 °C. 1H NMR (600 MHz, DCCl3): δ 2.32 (s, 3H), 2.43 (s, 3H), 2.45–2.49 (m, 4H), 2.59 (s, 3H), 3.40–3.51 (m, 4H), 6.40 (d, J = 12.8 Hz, 1H), 7.29–7.35 (m, 4H), 7.77 (d, J = 12.8 Hz, 1H). 13C{1H} NMR (151 MHz, DCCl3): δ 10.3, 21.3, 45.4, 46.1, 53.1, 54.0, 54.9, 93.7, 125.2, 130.2, 133.4, 136.5, 140.0, 144.5, 151.8, 183.3. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C18H24N5O, 326.1975; found, 326.1981.

(E)-1-(1-(4-Isopropylphenyl)-5-methyl-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10j)

Compound 10j was obtained in 98% (1039 mg) yield according to the general procedure (enaminone 1j: 895 mg, 5 min). After cooling to room temperature, the solid phase was separated, washed with Et2O twice, and with PE to afford pure enaminone 10j. Light yellow powder, mp 194–196 °C. 1H NMR (400 MHz, DCCl3): δ 1.28 (d, J = 6.9 Hz, 6H), 2.31 (s, 3H), 2.39–2.53 (m, 4H), 2.60 (s, 3H), 3.00 (dq, J = 13.8, 6.8 Hz, 1H), 3.34–3.55 (m, 4H), 6.40 (d, J = 12.8 Hz, 1H), 7.36 (q, J = 8.4 Hz, 4H), 7.77 (d, J = 12.8 Hz, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 10.3, 23.9, 34.0, 45.3, 46.1, 53.1, 54.4, 93.6, 125.3, 127.5, 133.6, 136.4, 144.5, 150.7, 151.7, 183.2. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C20H28N5O, 354.2288; found, 354.2293.

(E)-1-(1-(2-Chloro-4-methylphenyl)-5-methyl-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10k)

Compound 10k was obtained in 93% (972 mg) yield according to the general procedure (enaminone 1k: 914 mg, 1.5 h). The crude product was purified with column chromatography: applied as a solution in EtOAc, eluted successively with EtOAc and AcMe, and finally with EtOH. Portions of the eluate (EtOH), containing enaminone 10k, were combined, evaporated to dryness, and crystallized from n-octane. Light yellow crystals, mp 172–172 °C. 1H NMR (400 MHz, DCCl3): δ 2.32 (s, 3H), 2.43 (s, 3H), 2.46 (s, 3H), 2.44–2.49 (m, 4H), 3.39–3.51 (m, 4H), 6.41 (d, J = 12.9 Hz, 1H), 7.18–7.31 (m, 2H), 7.39 (s, 1H), 7.78 (d, J = 12.9 Hz, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 9.5, 21.1, 45.3, 46.0, 53.1, 54.3, 93.4, 128.6, 128.7, 130.8, 130.8, 131.3, 138.1, 142.5, 143.8, 151.7, 182.9. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C18H23ClN5O, 360.1586; found, 360.1599.

(E)-1-(1-(3-Chlorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10l)

Compound 10l was obtained in 97% (1006 mg) yield according to the general procedure (enaminone 1l: 872 mg, 1.7 h). The crude product was crystallized from PhH–PE. Light yellow powder, mp 178–180 °C. 1H NMR (400 MHz, DCCl3): δ 2.31 (s, 3H), 2.40–2.52 (m, 4H), 2.63 (s, 3H), 3.37–3.53 (m, 4H), 6.37 (d, J = 12.8 Hz, 1H), 7.35 (dd, J = 5.5, 2.8 Hz, 1H), 7.41–7.55 (m, 3H), 7.77 (d, J = 12.8 Hz, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 10.3, 45.3, 46.1, 53.1, 54.0, 54.6, 93.4, 123.4, 125.6, 129.9, 130.6, 135.3, 136.3, 136.8, 144.6, 151.9, 182.8. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C17H21ClN5O, 346.1429; found, 346.1445.

(E)-1-(1-(3-Fluorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10m)

Compound 10m was obtained in 97% (959 mg) yield according to the general procedure (enaminone 1m: 823 mg, 5 min). The crude product was crystallized from PhH–PE to obtain product 10m pure enough for the further syntheses. Analytically pure sample was prepared by column chromatography: applied as a solution on DCM, eluted successively with DCM and EtOAc, and finally with EtOAc/EtOH (1:1). Portions of the eluate, containing desired compound 10m, were combined, evaporated, and the residue was crystallized from PhH–PE. Light yellow powder, mp 183–185 °C. 1H NMR (400 MHz, DCCl3): δ 2.34 (s, 3H), 2.49 (d, J = 4.4 Hz, 4H), 2.66 (s, 3H), 3.35–3.58 (m, 4H), 6.39 (d, J = 12.8 Hz, 1H), 7.16–7.33 (m, 3H), 7.53 (dd, J = 14.5, 8.3 Hz, 1H), 7.78 (d, J = 12.8 Hz, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 10.3, 45.5, 46.1, 53.3, 54.4 (2C), 93.5, 113.1 (d, J = 24.7 Hz), 116.8 (d, J = 21.0 Hz), 121.0 (d, J = 3.4 Hz), 131.0 (d, J = 8.9 Hz), 136.4, 137.1 (d, J = 9.8 Hz), 144.7, 151.9, 162.8 (d, J = 249.5 Hz), 182.9. 19F{1H} NMR (376 MHz, DCCl3): δ −109.87. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C17H21FN5O, 330.1725; found, 330.173.

(E)-1-(5-Methyl-1-(2-nitrophenyl)-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10n)

Compound 10n was obtained in 83% (887 mg) yield according to the general procedure (enaminone 1n: 904 mg, 5 min). The crude product was treated with PE twice and purified by column chromatography: applied as a solution in DCM, eluted successively with DCM and EtOAc, and finally with EtOAc/EtOH (1:1). Portions of the eluate, containing product 10n, were combined, evaporated to dryness, and crystallized from PhH–PE to afford pure enaminone 10n. Light yellow powder, mp 158–160 °C. 1H NMR (400 MHz, DCCl3): δ 2.32 (s, 3H), 2.42–2.50 (m, 4H), 2.52 (s, 3H), 3.38–3.55 (m, 4H), 6.37 (d, J = 12.8 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.68–7.89 (m, 3H), 8.18 (d, J = 8.0 Hz, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 9.55, 45.4, 46.0, 53.2, 54.0, 54.8, 93.4, 125.8, 129.0, 129.6, 131.6, 134.2, 138.1, 144.2, 145.5, 151.9, 182.5. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C17H21N6O3, 357.167; found, 357.1677.

(E)-1-(5-Methyl-1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10o)

Compound 10o was obtained in 89% (952 mg) yield according to the general procedure (enaminone 1o: 904 mg, 2 min). After cooling to room temperature, the solid phase was separated, washed with Et2O twice, and with PE to afford pure enaminone 10o. Light yellow powder, mp 218–219 °C. 1H NMR (400 MHz, DCCl3): δ 2.32 (s, 3H), 2.41–2.56 (m, 4H), 2.71 (s, 3H), 3.37–3.55 (m, 4H), 6.37 (d, J = 12.7 Hz, 1H), 7.72 (d, J = 8.8 Hz, 2H), 7.78 (d, J = 12.8 Hz, 1H), 8.43 (d, J = 8.8 Hz, 2H). 13C{1H} NMR (101 MHz, DCCl3): δ 10.6, 45.6, 46.2, 53.4, 53.9, 55.0, 93.4, 125.2, 125.8, 136.3, 140.8, 145.2, 148.1, 152.2, 182.6. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C17H21N6O3, 357.1670; found, 357.1676.

1-((2R,5S)-5-(Hydroxymethyl)-4-(5-methyl-4-((E)-3-(4-methylpiperazin-1-yl)acryloyl)-1H-1,2,3-triazol-1-yl)tetrahydrofuran-2-yl)-3,5-dimethylpyrimidine-2,4(1H,3H)-dione (10p)

Compound 10p was obtained in 86% (1222 mg) yield according to the general procedure (enaminone 1p: 1255 mg, 2 h). The crude product was washed with PE and crystallized from MeOH. Light yellow powder, mp 187–188 °C. 1H NMR (400 MHz, DCCl3): δ 1.93 (s, 3H), 2.31 (s, 3H), 2.38–2.52 (m, 4H), 2.64 (s, 3H), 2.97 (dd, J = 10.5, 4.6 Hz, 2H), 3.33 (s, 3H), 3.43 (s, 4H), 3.66 (d, J = 12.1 Hz, 1H), 3.81 (s, 1H), 4.00 (d, J = 12.1 Hz, 1H), 4.40–4.54 (m, 1H), 5.29 (dd, J = 13.4, 6.1 Hz, 1H), 6.23 (t, J = 6.5 Hz, 1H), 6.28 (d, J = 12.8 Hz, 1H), 7.38 (s, 1H), 7.74 (d, J = 12.8 Hz, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 9.1, 13.3, 27.9, 37.4, 45.4, 46.1, 54.5, 55.9, 61.5, 85.3, 90.2, 93.3, 110.3, 136.0, 136.1, 144.6, 151.1, 152.1, 163.6, 183.0. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C22H32N7O5, 474.2459; found, 474.24.

(E)-1-(5-Methyl-1,2,3-thiadiazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10q)

Compound 10q was obtained in 97% (734 mg) yield according to the general procedure (enaminone 1q: 592 mg, 10 min). The crude product was treated with a small amount of PE, the residue was crystallized from n-heptane. Light yellow powder, mp 125–126 °C. 1H NMR (600 MHz, DCCl3): δ 2.31 (s, 3H), 2.46 (d, J = 4.1 Hz, 4H), 2.91 (s, 3H), 3.45 (s, 4H), 6.50 (d, J = 12.1 Hz, 1H), 7.78 (d, J = 12.7 Hz, 1H). 13C{1H} NMR (151 MHz, DCCl3): δ 11.2, 45.5, 46.1, 53.5, 53.8, 55.1, 95.1, 152.9, 156.8, 157.8, 182.4. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C11H17N4OS, 253.1118; found, 253.1124.

(E)-1-(3-(4-Chlorophenyl)-5-methylisoxazol-4-yl)-3-(4-methylpiperazin-1-yl)prop-2-en-1-one (10r)

Compound 10r was obtained in 73% (757 mg) yield according to the general procedure (enaminone 1r: 872 mg, 5 min). The reaction mixture was left at room temperature for 12 h, the formed precipitate was separated, washed with PE, and crystallized from n-heptane. Light yellow powder, mp 164–166 °C. 1H NMR (400 MHz, DCCl3): δ 2.28 (br s, 3H), 2.33 (s, 4H), 2.60 (s, 3H), 3.00 (br s, 2H), 3.29 (br s, 2H), 5.01 (d, J = 12.7 Hz, 1H), 7.38 (d, J = 8.5 Hz, 2H), 7.41 (d, J = 12.7 Hz, 1H), 7.58 (d, J = 8.5 Hz, 2H). 13C{1H} NMR (151 MHz, DCCl3): δ 12.8, 45.2, 46.1, 53.2, 53.5, 53.6, 55.0, 97.1, 117.7, 130.5, 135.8, 152.4, 160.3, 171.5, 183.7. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C18H21ClN3O2, 346.1317; found, 346.1328.

General Procedure for the Preparation of NH-1,2,3-Triazoles 4

A solution of enaminone 10 (1.0 mmol) and TsN3 (2a, 1.0 mmol, 197 mg) in PyH (4.6 g) was kept at ambient temperature (for 4-nitro derivative 10o, at 80 °C, for 1,2,3-thiadiazole 10q and isoxazole 10r derivatives, at 52 °C) for 2–50 h. Volatiles were evaporated to dryness, the residue was treated with a mixture of H2O (6 g) and AcOH (350 mg), followed once again by the same mixture, finally with H2O (6 g), and dried. While preparing triazoles 4d and 4o, aqueous acetic washes were used for the isolation of 1-methyl-4-tosylpiperazine (6a) and 4-methyl-N-((4-methylpiperazin-1-yl)methylene)benzenesulfonamide in an oxalate form (7aa), respectively. The details are available from specific protocols of the synthesis. Content of NH-triazole 4 and diazo compound 5 in the mixture was estimated based on 1H NMR. Pure products 4 and 5 were isolated with column chromatography of the mixture: applied as a solution in DCM with an addition of Et3N (5 drops per 10 mL), eluted successively with DCM and EtOAc, and finally with EtOAc with an addition of AcOH (5 drops per 10 mL). Portions of the eluate, containing products 4 and 5, were combined, evaporated to dryness, and crystallized.

(1-Phenyl-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4a)

Compound 4a was obtained in 94% (226 mg) yield according to the general procedure (enaminone 10a: 297 mg, 4 h). Colorless powder, mp 247–249 °C (i-PrOH/Et2O). 1H NMR (400 MHz, DMSO-d6): δ 7.56 (t, J = 7.4 Hz, 1H), 7.65 (t, J = 7.7 Hz, 2H), 8.03 (d, J = 7.8 Hz, 2H), 8.99 (s, 1H), 9.67 (s, 1H), 15.96 (br s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 120.8, 127.7, 129.4, 129.9, 131.8, 136.1, 143.8, 146.1. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C11H8N6O, 241.0832; found, 241.0834.

(1-(p-Tolyl)-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4b)

Compound 4b was obtained in 92% (234 mg) yield according to the general procedure (enaminone 10b: 311 mg, 5 h). Colorless powder, mp 229–230 °C (H2O). 1H NMR (400 MHz, DMSO-d6): δ 2.40 (s, 3H), 7.43 (d, J = 8.3 Hz, 2H), 7.90 (d, J = 8.4 Hz, 2H), 8.98 (s, 1H), 9.61 (s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 20.6, 120.6, 127.6, 130.3, 131.7, 133.8, 139.2, 144.0, 146.0, 175.8. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C11H10N5O, 228.0880; found, 228.0881.

(1-(2-Nitrophenyl)-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4c)

Compound 4c was obtained in 96% (274 mg) yield according to the general procedure (enaminone 10c: 342 mg, 12 h). Light gray powder, mp 230–233 °C (EtOH, decomp.) 1H NMR (400 MHz, DMSO-d6): δ 7.86–7.97 (m, 1H), 8.02 (d, J = 3.3 Hz, 2H), 8.31 (d, J = 8.0 Hz, 1H), 8.98 (br s, 1H), 9.69 (s, 1H), 15.97 (br s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6 + Cs2CO3): δ 125.7, 128.4, 128.8, 131.5, 131.8, 132.5, 134.7, 143.9, 144.3, 145.7, 175.8. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C11H8N7O3, 286.0683; found, 286.0687.

(1-(4-Nitrophenyl)-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4d)

Compound 4d was obtained in 96% (274 mg) yield according to the general procedure (enaminone 10d: 342 mg, 12 h). Gray powder, mp 252–256 °C (treated with EtOH and Et2O, decomp.). For better characterization by the 13C NMR spectrum, acetate salt 4da was prepared. 1H NMR (400 MHz, DMSO-d6): δ 8.37 (d, J = 9.1 Hz, 2H), 8.48 (d, J = 9.1 Hz, 2H), 9.01 (br s, 1H), 9.88 (s, 1H), 15.98 (br s, 1H). For 4da: 13C{1H} NMR (101 MHz, DMSO-d6): δ 22.5, 121.5, 125.5, 128.1, 133.9, 140.6, 144.3, 147.1, 174.2, 176.2. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H8N7O3, 286.0683; found, 286.0688.

1-Methyl-4-tosylpiperazine (6a)

Aqueous acetic acid washes were combined and evaporated to dryness. The residue was treated with aqueous NH3, washed with water, and dried. A crude product was purified with column chromatography: applied as a solution in DCM and eluted successively with DCM and DCM/EtOAc (1:1). Portions of the eluate, containing the desired product 6a, were combined, evaporated to dryness, and the residue was crystallized from PhH–PE. Yield 84% (213 mg), colorless solid, mp 144–147 °C (lit.[56] 143–145 °C).

(1,5-Dimethyl-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-5-yl)methanone (4e)

Compound 4e was obtained in 95% (183 mg) yield according to the general procedure (enaminone 10e: 249 mg, 3 h). Colorless powder, mp 169–172 °C (H2O). 1H NMR (400 MHz, DMSO-d6): δ 2.59 (s, 3H), 4.01 (s, 3H), 8.91 (br s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 8.6, 33.9, 132.5, 139.3, 142.0, 142.5, 177.2. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C7H9N6O, 193.0832; found, 193.0837.

(1-Butyl-5-methyl-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4f)

Compound 4f was obtained in 91% (213 mg) yield according to the general procedure (enaminone 10f: 291 mg, 3 h). Gray powder, mp 138–140 °C (PhH–PE). 1H NMR (600 MHz, DMSO-d6): δ 0.90 (t, J = 7.4 Hz, 3H), 1.30 (dd, J = 15.0, 7.5 Hz, 2H), 1.71–1.85 (m, 2H), 2.62 (s, 3H), 4.37 (t, J = 7.2 Hz, 2H), 8.92 (s, 1H), 15.81 (br s, 1H). 13C{1H} NMR (151 MHz, DMSO-d6): δ 9.3, 13.8, 19.6, 31.4, 133.1, 139.6, 142.6, 143.6, 147.4, 177.8. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C10H15N6O, 235.1302; found, 235.1306.

(1-(4-Bromobenzyl)-5-methyl-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4g)

Compound 4g was obtained in 79% (274 mg) yield together with diazo compound 5g in 13% yield (42 mg) according to the general procedure (enaminone 10g: 404 mg, 3 h). Colorless powder, mp 162–164 °C (PhH–PE). 1H NMR (600 MHz, DMSO-d6): δ 2.58 (s, 3H), 5.69 (s, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H), 8.94 (s, 1H). 13C{1H} NMR (151 MHz, DMSO-d6): δ 9.5, 50.5, 121.9, 130.3, 132.3, 133.2, 134.9, 140.0, 142.9, 143.2, 177.8. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C13H12BrN6O, 347.0250; found, 347.0263.

(5-Methyl-1-phenyl-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4h)

Compound 4h was obtained in 89% (226 mg) yield together with diazo compound 5h in 5% yield (11 mg) according to the general procedure (enaminone 10h: 311 mg, 67 h). Colorless powder, mp 200–202 °C (EtOH). 1H NMR (600 MHz, MHz, DMSO-d6): δ 2.60 (s, 3H), 7.54–7.72 (m, 5H), 9.03 (br s, 1H), 15.87 (br s, 1H). 13C{1H} NMR (151 MHz, DMSO-d6 + Cs2CO3): δ 10.1, 125.6, 129.8, 130.3, 133.1, 135.0, 139.9, 142.4, 143.0, 177.5. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H11N6O, 255.0989; found, 255.0994.

[5-Methyl-1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl](1H-1,2,3-triazol-4-yl)methanone (4i)

Compound 4i was obtained in 96% (258 mg) yield according to the general procedure (enaminone 10i: 325 mg, 3 h). Gray powder, mp 148–151 °C (i-PrOH–H2O). 1H NMR (400 MHz, DMSO-d6): δ 2.43 (s, 3H), 2.58 (s, 3H), 7.47 (d, J = 8.1 Hz, 2H), 7.55 (d, J = 8.1 Hz, 2H), 8.96 (s, 1H). 13C{1H} NMR (151 MHz, DMSO-d6 + Cs2CO3): δ 10.5, 21.2, 125.8, 130.6, 133.0, 133.7, 140.2, 140.6, 142.9, 143.4, 178.0. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C13H13N6O, 269.1145; found, 269.1150.

(1-(4-Isopropylphenyl)-5-methyl-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4j)

Compound 4j was obtained in 80% (215 mg) yield together with diazo compound 5j in 14% yield (38 mg) according to the general procedure (enaminone 10j: 354 mg, 3 h). Gray powder, mp 217–220 °C (EtOH). 1H NMR (400 MHz, DMSO-d6): δ 1.27 (d, J = 6.9 Hz, 6H), 2.60 (s, 3H), 3.03 (dt, J = 13.7, 6.9 Hz, 1H), 7.56 (dd, J = 22.3, 8.5 Hz, 4H), 9.01 (s, 1H), 15.84 (br s, 1H). 13C{1H} NMR (151 MHz, DMSO-d6 + Cs2CO3): δ 10.5, 24.2, 33.7, 125.9, 128.1, 133.2, 133.4, 140.4, 142.8, 143.4, 151.2, 178.0. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C15H17N6O, 297.1458; found, 297.1460.

(1-(2-Chloro-4-methylphenyl)-5-methyl-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4k)

Compound 4k was obtained in 85% (257 mg) yield together with diazo compound 5k in 9% yield (25 mg) according to the general procedure (enaminone 10k: 360 mg, 36 h). Colorless powder, mp 211–213 °C (EtOH–H2O, decomp.). 1H NMR (600 MHz, DMSO-d6): δ 2.45 (s, 3H), 2.46 (s, 3H), 7.46 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.69 (s, 1H), 9.04 (s, 1H). 13C{1H} NMR (151 MHz, DMSO-d6): δ 9.9, 21.0, 129.7, 129.8, 130.0, 130.4, 131.2, 133.0, 141.9, 142.2, 143.4, 144.0, 177.7. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C13H12ClN6O, 303.0756; found, 303.0761.

(1-(3-Chlorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone 4l

Compound 4l was obtained in 91% (263 mg) yield according to the general procedure (enaminone 10l: 346 mg, 4 h). Colorless needles, mp 195–196 °C. 1H NMR (400 MHz, DMSO-d6 + Cs2CO3): δ 2.62 (s, 3H), 7.72 (dd, J = 13.4, 4.3 Hz, 3H), 7.87 (s, 1H), 9.01 (br s, 1H), 15.88 (br s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6 + Cs2CO3): δ 10.0, 124.5, 125.6, 130.3, 131.4, 133.0, 134.0, 136.1, 140.2, 142.4, 143.0, 177.5. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H10ClN6O, 289.0599; found, 289.0608.

(1-(3-Fluorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4m)

Gray powder, mp 180–181 °C. Compound 4m was obtained in 97% (264 mg) yield according to the general procedure (enaminone 10m: 329 mg, 3 h). 1H NMR (400 MHz, DMSO-d6): δ 2.63 (d, J = 1.6 Hz, 3H), 7.47–7.64 (m, 2H), 7.64–7.80 (m, 2H), 15.90 (br s, 1H), 9.01 (s, 1H). 13C NMR (101 MHz, DMSO-d6): δ 10.0, 113.2 (d, J = 25.1 Hz), 117.3 (d, J = 20.9 Hz), 121.8 (d, J = 3.2 Hz), 128.2, 131.6 (d, J = 9.1 Hz), 132.7, 136.1 (d, J = 10.4 Hz), 141.2 (d, J = 191.9 Hz), 142.8, 162.0 (d, J = 246.5 Hz), 177.3. 19F{1H} NMR (376 MHz, DMSO-d6): δ −110.47. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H10FN6O, 273.0895; found, 273.0897.

(5-Methyl-1-(2-nitrophenyl)-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4n)

Compound 4n was obtained in 98% (356 mg) yield according to the general procedure (enaminone 10n: 346 mg, 4 h). Colorless powder, mp 201–203 °C (i-PrOH). 1H NMR (400 MHz, DMSO-d6): δ 2.58 (s, 3H), 7.93–8.04 (m, 2H), 8.08 (t, J = 7.3 Hz, 1H), 8.38 (d, J = 7.9 Hz, 1H), 9.04 (s, 1H). 13C NMR (101 MHz, DMSO-d6 + Cs2CO3): δ 9.5, 126.1, 127.3, 129.7, 132.7, 133.2, 135.1, 141.5, 142.2, 143.0, 145.1, 177.4. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H10N7O3, 300.084; found, 300.0845.

(5-Methyl-1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4o)

Compound 4o was obtained in 75% (224 mg) yield according to the general procedure at 80 °C (enaminone 10o: 356 mg, 1.5 h). Gray powder, mp 274–278 °C (decomp.). 1H NMR (400 MHz, DMSO-d6): δ 2.68 (s, 3H), 8.03 (d, J = 8.5 Hz, 2H), 8.50 (d, J = 8.5 Hz, 2H), 9.02 (s, 1H), 15.90 (s, 1H). 13C NMR (101 MHz, DMSO-d6+Cs2CO3): δ 10.1, 125.1, 126.7, 133.1, 139.8, 140.3, 142.7, 143.0, 148.0, 177.4. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H10N7O3, 300.0840; found, 300.0833.

4-Methyl-N-((4-methylpiperazin-1-yl)methylene)benzenesulfonamide Oxalate (7aa)

Aqueous acetic acid washes were combined and evaporated to dryness. The residue was purified with column chromatography: applied as a solution in DCM with the addition of Et3N (5 drops per 10 mL), eluted successively with DCM and EtOAc, and EtOAc/EtOH (1:1). Portions of the eluate, containing the desired product 7aa, were combined and evaporated to dryness. The oily residue was dissolved in EtOH (1700 mg) and warmed to 45 °C. To this solution, oxalic acid (35 mg, 0.39 mmol) was added at once. The solution was left to cool to room temperature and kept for 2 h, while the solid phase forms gradually. It was separated, washed with Et2O twice, and dried. Yield 18% (67 mg), beige powder, mp 189–191 °C (EtOH). 1H NMR (400 MHz, DMSO-d6): δ 2.36 (s, 3H), 2.53 (s, 3H), 2.84 (t, J = 5.0 Hz, 2H), 2.89–2.96 (m, 2H), 3.66 (d, J = 4.8 Hz, 2H), 3.70–3.80 (m, 2H), 7.34 (d, J = 8.2 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H), 8.29 (s, 1H), 10.41 (br s, 1H). 13C{1H} NMR (151 MHz, DMSO-d6): δ 21.0, 40.9, 43.3, 47.1, 51.8, 52.9, 126.1, 129.5, 139.8, 142.2, 158.7, 163.9. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C13H20N3O2S, 282.1271; found, 282.1278.

1-((2R,5S)-5-(Hydroxymethyl)-4-(5-methyl-4-(1H-1,2,3-triazole-4-carbonyl)-1H-1,2,3-triazol-1-yl)tetrahydrofuran-2-yl)-3,5-dimethylpyrimidine-2,4(1H,3H)-dione (4p)

Compound 4p was obtained in 96% (400 mg) yield according to the general procedure (enaminone 10p: 474 mg, 1 h). Colorless powder, mp 172–177 °C. 1H NMR (400 MHz, DMSO-d6): δ 1.88 (s, 3H), 2.67–2.73 (m, 4H), 2.86 (dd, J = 14.1, 4.7 Hz, 1H), 3.19 (s, 3H), 3.61–3.80 (m, 2H), 4.34 (d, J = 3.6 Hz, 1H), 5.23–5.34 (m, 1H), 6.59 (t, J = 6.7 Hz, 1H), 7.89 (s, 1H), 8.97 (s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6 + Cs2CO3): δ 9.0, 13.0, 27.5, 37.0, 57.4, 61.0, 84.7, 85.6, 108.7, 133.8, 134.5, 139.3, 142.6, 143.1, 150.6, 162.9, 177.8. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C17H21N8O5, 417.1629; found, 417.1638.

(5-Methyl-1,2,3-thiadiazol-4-yl)(1H-1,2,3-triazol-4-yl)methanone (4q)

Compound 4q was obtained in 78% (131 mg) yield according to the general procedure (enaminone 10q: 252 mg, 2 h at 52 °C). Beige powder, mp 171–173 °C (i-PrOH). 1H NMR (400 MHz, DMSO-d6): δ 2.91 (s, 3H), 9.00 (br s, 1H), 15.86 (br s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 11.5, 133.2, 144.7, 156.1, 162.0, 178.0. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C6H6N5OS, 196.0288; found, 196.0294.

(3-(4-Chlorophenyl)-5-methylisoxazol-4-yl)(1,2,3-triazol-4-yl)methanone (4r)

Compound 4r was obtained in 85% (245 mg) yield according to the general procedure (enaminone 10r: 346 mg, 4 h at 52 °C). Colorless powder, mp 154–155 °C (EtOH–H2O). 1H NMR (400 MHz, DMSO-d6): δ 2.53 (s, 3H), 7.47 (s, 4H), 8.62 (s, 1H), 15.74 (br s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 12.7, 115.6, 127.1, 128.6, 130.0, 131.1, 134.6, 145.6, 160.6, 173.4, 180.7. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C13H10ClN4O2, 289.0487; found 289.0493.

General Procedure for the Preparation of Diazo Ketones 5

A mixture of enaminone 10 (1.0 mmol) and 4-nitrophenylsylfonyl azide (2e, 1.0 mmol) in EtOH (4.8 g) was stirred at room temperature (at 80 °C for enaminone 13p) for 2–49 h. The solid phase [main amount of N-((4-methylpiperazin-1-yl)methylene)-4-nitrobenzenesulfonamide (7b)] was separated, the liquid phase was evaporated to dryness. The residue was treated with a mixture of H2O (6.0 g) and AcOH (313 mg), once again with the same mixture and finally with water (6.0 g). While preparing diazo compound 5c, aqueous acetic washes were used for the isolation of 1-methyl-4-((4-nitrophenyl)sulfonyl)piperazine (6b). The details are available from a specific protocol of the synthesis. The separation of multicomponent mixtures thus obtained, containing diazo compounds 5 and NH-1,2,3-triazoles 4, and purification of crude products were performed similarly to the general procedure for the preparation of NH-1,2,3-triazoles 4 (see above). For diazo compounds 5e and 5f, which are well soluble in water, the modified work-up was applied (see the specific procedure).

2-Diazo-1-(1-phenyl-1H-1,2,3-triazol-4-yl)ethan-1-one (5a)

Compound 5a was obtained in 85% (181 mg) yield together with compound 4a in 9% (22 mg) yield according to the general procedure (enaminone 10a: 297 mg, 23 h). Light yellow powder, mp 192–193 °C (PhH–PE, decomp.). IR (ATR, ZnSe, cm–1): ν 2104 (N–N stretch), 1615, 1540, 1367, 861, 734. 1H NMR (400 MHz, DMSO-d6): δ 6.81 (s, 1H), 7.45–7.74 (m, 3H), 7.97 (d, J = 7.6 Hz, 2H), 9.43 (s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 55.2, 120.5, 124.3, 129.3, 129.9, 136.1, 146.3, 178.5. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C10H8N5O, 214.0723; found, 214.0729.

2-Diazo-1-(1-(p-tolyl)-1H-1,2,3-triazol-4-yl)ethan-1-one (5b)

Compound 5b was obtained in 84% (191 mg) yield together with compound 4b in 9% (23 mg) yield according to the general procedure (enaminone 10b: 311 mg, 22 h). Light yellow powder, mp 168–169 °C (n-octane, decomp.). IR (ATR, ZnSe, cm–1): ν 3058, 2104 (N–N stretch), 1617, 1541, 1368, 1027, 862, 810, 748. 1H NMR (600 MHz, DMSO-d6): δ 2.39 (s, 3H), 6.76 (s, 1H), 7.41 (d, J = 8.2 Hz, 2H), 7.79–7.89 (m, 2H), 9.33 (s, 1H). 13C{1H} NMR (151 MHz, DMSO-d6): δ 21.0, 55.6, 120.9, 124.6, 130.7, 134.4, 139.5, 146.7, 178.9. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C11H10N5O, 228.0880; found, 228.0881.

2-Diazo-1-(1-(2-nitrophenyl)-1H-1,2,3-triazol-4-yl)ethan-1-one (5c)

Compound 5c was obtained in 80% (206 mg) yield together with compound 4c in 10% (29 mg) yield according to the general procedure (enaminone 10c: 342 mg, 48 h). Light yellow powder, mp 158–159 °C (PE, decomp.). IR (ATR, ZnSe, cm–1): ν 2203 (N–N stretch), 1720, 1531, 1189. 1H NMR (400 MHz, DCCl3): δ 6.48 (s, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.77 (d, J = 7.6 Hz, 1H), 7.83 (d, J = 7.6 Hz, 1H), 8.15 (d, J = 7.2 Hz, 1H), 8.41 (s, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 55.3, 126.0, 126.4, 128.1, 129.9, 131.6, 134.2, 144.6, 147.0, 178.7. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C10H7N6O3, 259.0574; found, 259.0601.

1-Methyl-4-((4-nitrophenyl)sulfonyl)piperazine (6b)

Aqueous acetic acid washes were combined and evaporated to dryness. The residue was treated with aqueous NH3, washed with water, and dried. A crude product was purified with column chromatography: applied as a solution in DCM and eluted successively with DCM and DCM/EtOAc (1:1). Portions of the eluate, containing the desired product 6b, were combined, evaporated to dryness, and the residue was crystallized from PhH–PE. Yield 13% (44 mg), light brown powder, mp 155–156 °C (PhH–PE). 1H NMR (400 MHz, DCCl3): δ 2.26 (s, 3H), 2.41–2.55 (m, 4H), 3.09 (br s, 4H), 7.94 (d, J = 8.7 Hz, 2H), 8.37 (d, J = 8.7 Hz, 2H). 13C{H} NMR (101 MHz, DCCl3): δ 45.8, 46.0, 54.1, 124.4, 129.0, 141.9, 150.4. By 1H NMR spectrum, the product corresponds to 1-methyl-4-((4-nitrophenyl)sulfonyl)piperazine (6b), described earlier.[57]

2-Diazo-1-(1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)ethan-1-one 5d

Compound 5d was obtained in 79% (204 mg) yield together with compound 4d in 9% (27 mg) yield according to the general procedure (enaminone 10d: 342 mg, 46 h). Light yellow powder, 202–204 °C (n-BuOH, decomp.). IR (ATR, ZnSe, cm–1): ν 3114, 2115 (N–N stretch), 1596, 1518, 1363, 1345, 859. 1H NMR (400 MHz, DMSO-d6): δ 6.82 (br s, 1H), 8.29 (d, J = 9.0 Hz, 2H), 8.45 (d, J = 9.0 Hz, 2H), 9.63 (s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 55.4, 121.3, 124.9, 125.4, 140.4, 146.6, 147.3, 178.1. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C10H7N6O3, 259.0574; found, 259.0573.

2-Diazo-1-(1,5-dimethyl-1H-1,2,3-triazol-4-yl)ethan-1-one (5e)

Compound 5e was obtained in 89% (147 mg) yield together with compound 4e in 6% yield according to the modified general procedure (enaminone 10e: 249 mg, 3 h). Liquid phases after the removal of the main amount of amidine 7b were combined and evaporated to dryness. According to the 1H NMR spectrum, the mixture contained NH-triazole 4e in 5% (6 mg) yield. To isolate diazo compound 5e, the mixture was separated with column chromatography: applied as a solution in DCM and eluted successively with DCM and DCM/EtOAc (1:1). Portions, containing diazo compound 5e, were combined, evaporated to dryness, and the residue was crystallized from PE to afford pure diazo compound 5e. Light yellow powder, mp 129–130 °C (PE). IR (ATR, ZnSe, cm–1): ν 2097 (N–N stretch), 1608, 1570, 1360, 1309, 1020, 864, 570, 516. 1H NMR (400 MHz, DCCl3): δ 2.58 (s, 3H), 3.96 (s, 3H), 6.39 (s, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 8.8, 34.2, 54.3, 136.1, 141.9, 180.9. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C6H8N5O, 166.0723; found, 166.0728.

N-((4-Methylpiperazin-1-yl)methylene)-4-nitrobenzenesulfonamide (7b)

Beige powder, mp 200–202 °C. 1H NMR (600 MHz, DMSO-d6): δ 2.19 (s, 3H), 2.31 (t, J = 4.9 Hz, 2H), 2.37–2.42 (m, 2H), 3.50–3.57 (m, 2H), 3.57–3.63 (m, 2H), 8.03 (d, J = 8.8 Hz, 2H), 8.33 (s, 1H), 8.35 (d, J = 8.8 Hz, 2H). 13C{1H} NMR (151 MHz, DMSO-d6): δ 43.2, 45.4, 49.6, 53.3, 54.5, 124.4, 127.52, 148.3, 149.2, 158.7. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H17N4O4S, 313.0971; found, 313.0973.

1-(1-Butyl-5-methyl-1H-1,2,3-triazol-4-yl)-2-diazoethanone (5f)

Compound 5f was obtained in 94% (195 mg) yield according to the same procedure as for the preparation of compound 5e (enaminone 10e: 291 mg, 3 h). Yellowish oil. IR (ATR, ZnSe, cm–1): ν 2104 (N–N stretch), 1621, 1570, 1364, 1315, 864. 1H NMR (400 MHz, DCCl3): δ 0.95 (t, J = 7.4 Hz, 3H), 1.35 (dd, J = 15.0, 7.5 Hz, 2H), 1.78–1.90 (m, 2H), 2.59 (s, 3H), 4.25 (t, J = 7.3 Hz, 2H), 6.41 (br s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 8.9, 13.5, 19.8, 31.7, 47.6, 54.3, 135.5, 141.8, 181.0. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C9H14N5O, 208.1193; found, 208.1202.

1-(1-(4-Bromobenzyl)-5-methyl-1H-1,2,3-triazol-4-yl)-2-diazoethan-1-one (5g)

Compound 5g was obtained in 82% (263 mg) yield according to the general procedure (enaminone 10g: 404 mg, 4 h). Light yellow powder, mp 104–108 °C (PE, decomp.). IR (ATR, ZnSe, cm–1): ν 2096 (N–N stretch), 1610, 1562, 1367, 1007. 1H NMR (400 MHz, DCCl3): δ 2.50 (s, 3H), 5.45 (s, 2H), 6.43 (br s, 1H), 7.05 (d, J = 8.5 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H). 13C{1H} NMR (101 MHz, DCCl3): δ 8.9, 51.1, 54.5, 122.8, 128.9, 132.3, 132.9, 135.9, 142.2, 180.7. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H11BrN5O, 320.0141; found, 320.0151.

2-Diazo-1-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)ethan-1-one (5h)

Compound 5h was obtained in 88% (200 mg) yield according to the general procedure (enaminone 10h: 311 mg, 20 h). Light yellow powder, mp 97–100 °C (PE). IR (ATR, ZnSe, cm–1): ν 3063, 2108 (N–N stretch), 1623, 1608, 1563, 1364, 1324, 865, 760. 1H NMR (400 MHz, DMSO-d6): δ 2.60 (s, 3H), 6.48 (s, 1H), 7.39–7.48 (m, 2H), 7.55 (d, J = 7.0 Hz, 3H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 9.5, 54.8, 125.4, 129.7, 130.1, 135.0, 136.7, 141.0, 180.2. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C11H10N5O, 228.0880; found, 228.0881.

2-Diazo-1-[5-methyl-1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl]ethan-1-one (5i)

Compound 5i was obtained in 86% (208 mg) yield according to the general procedure (enaminone 10i: 325 mg, 3 h). Light yellow powder, mp 117–120 °C (PE). IR (ATR, ZnSe, cm–1): ν 2102 (N–N stretch), 1613, 1364, 822. 1H NMR (400 MHz, DCCl3): δ 2.45 (s, 3H), 2.59 (s, 3H), 6.49 (br s, 1H), 7.31 (dd, J = 6.2, 4.0 Hz, 2H), 7.36 (d, J = 8.3 Hz, 2H). 13C{1H} NMR (101 MHz, DCCl3): δ 10.0, 21.4, 54.6, 125.1, 130.3, 133.0, 136.6, 140.5, 141.9, 180.9. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H12N5O, 242.1036; found, 242.1043.

2-Diazo-1-(1-(4-isopropylphenyl)-5-methyl-1H-1,2,3-triazol-4-yl)ethan-1-one (5j)

Compound 5j was obtained in 92% (248 mg) yield according to the general procedure (enaminone 10j: 354 mg, 4 h). Light yellow powder, mp 103–104 °C (PE). IR (ATR, ZnSe, cm–1): ν 2100 cm–1 (N2), 1610, 1560, 1512, 1363, 1318, 1270, 860, 574, 515. 1H NMR (400 MHz, DCCl3): δ 1.29 (d, J = 6.9 Hz, 6H), 2.60 (s, 3H), 3.00 (dt, J = 13.8, 6.9 Hz, 1H), 6.49 (br s, 1H), 7.34 (d, J = 8.6 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H). 13C{1H} NMR (101 MHz, DCCl3): δ 9.9, 23.8, 34.0, 54.5, 125.1, 127.7, 133.1, 136.5, 141.7, 151.1, 180.8. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C14H16N5O, 270.1349; found, 270.1354.

1-(1-(2-Chloro-4-methylphenyl)-5-methyl-1H-1,2,3-triazol-4-yl)-2-diazoethan-1-one (5k)

Compound 5k was obtained in 83% (229 mg) yield according to the general procedure (enaminone 10k: 360 mg, 24 h). Light yellow powder, mp 142–146 °C (PhH–PE). IR (ATR, ZnSe, cm–1): ν 2106 (N–N stretch), 1619, 1367, 993, 864, 839. 1H NMR (600 MHz, DCCl3): δ 2.44 (s, 3H), 2.45 (s, 3H), 6.49 (s, 1H), 7.29–7.22 (m, 2H), 7.41 (s, 1H). 13C{1H} NMR (151 MHz, DCCl3): δ 9.3, 21.2, 54.6, 128.7, 128.7, 130.3, 131.0, 131.2, 138.3, 141.2, 143.0, 180.7. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H11ClN5O, 276.0647; found, 276.0650.

1-(1-(3-Chlorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)-2-diazoethan-1-one (5l)

Compound 5l was obtained in 87% (228 mg) yield according to the general procedure (enaminone 10l: 346 mg, 4 h). Light yellow powder, mp 90–92 °C (PhH–PE). IR (ATR, ZnSe, cm–1): ν 3070, 2106 cm–1 (N–N stretch), 1630, 1561, 1486, 1433. 1H NMR (400 MHz, DCCl3): δ 2.64 (s, 3H), 6.49 (br s, 1H), 7.36 (d, J = 7.0 Hz, 1H), 7.66–7.44 (m, 3H). 13C{1H} NMR (101 MHz, DCCl3): δ 10.0, 54.9, 123.4, 125.6, 130.4, 130.8, 135.6, 136.4, 136.6, 142.0, 180.7. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C11H9ClN5O, 262.0490; found, 262.0489.

2-Diazo-1-(1-(3-fluorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)ethan-1-one (5m)

Compound 5m was obtained in 68% (167 mg) yield according to the general procedure (enaminone 10n: 329 mg, 4 h). Light yellow powder, mp 107–109 °C (n-heptane). IR (ATR, ZnSe, cm–1): ν 2100 (N–N stretch), 1620, 1384, 873, 857, 789, 518. 1H NMR (400 MHz, DCCl3): δ 2.63 (s, 3H), 6.47 (s, 1H), 7.28–7.20 (m, 3H), 7.61–7.47 (m, 1H). 13C{1H} NMR (101 MHz, DCCl3): δ 9.9, 54.7, 113.0 (d, J = 24.6 Hz), 117.2 (d, J = 20.9 Hz), 120.8 (d, J = 3.4 Hz), 131.1 (d, J = 8.9 Hz), 136.5 (d, J = 4.9 Hz), 136.6, 141.9, 162.7 (d, J = 248.6 Hz), 180.6. 19F{1H} NMR (376 MHz, DCCl3): δ −109.43. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C11H9FN5O, 246.0786; found, 246.0787.

2-Diazo-1-(5-methyl-1-(2-nitrophenyl)-1H-1,2,3-triazol-4-yl)ethan-1-one (5n)

Compound 5n was obtained in 76% (207 mg) yield according to the general procedure (enaminone 10n: 356 mg, 4 h). Yellow powder, mp 95–98 °C (n-octane). IR (ATR, ZnSe, cm–1): ν 3075, 2103 (CHN2), 1612, 1529, 1306, 995, 866. 1H NMR (400 MHz, DCCl3): δ 2.55 (s, 3H), 6.48 (s, 1H), 7.50 (dd, J = 7.7, 1.4 Hz, 1H), 7.83 (dtd, J = 24.8, 7.7, 1.5 Hz, 2H), 8.22 (dd, J = 8.0, 1.5 Hz, 1H). 13C{1H} NMR (101 MHz, DCCl3, APT mode): δ 9.3, 54.8, 126.0, 128.6, 129.6, 132.0, 134.3, 138.4, 141.5, 145.38, 180.4. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C11H9N6O3, 273.0731; found, 273.0755.

2-Diazo-1-(5-methyl-1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)ethan-1-one (5o)

Compound 5o was obtained in 92% (250 mg) yield according to the general procedure (enaminone 10o: 356 mg, 2 h at 80 °C). Light yellow powder, mp 172–174 °C (DCM–PE, decomp.). IR (ATR, ZnSe, cm–1): ν 2112 (N–N stretch), 1526, 1501, 1345. 1H NMR (400 MHz, DMSO-d6): δ 2.63 (s, 3H), 6.70 (s, 1H), 7.96 (d, J = 9.0 Hz, 2H), 8.46 (d, J = 9.0 Hz, 2H). 13C{1H} NMR (101 MHz, DMSO-d6, APT mode): δ 9.5, 54.9, 125.0, 126.4, 137.2, 139.9, 141.5, 148.0, 179.9. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C11H9N6O3, 273.0731; found, 273.0728.

1-((2R,5S)-4-(4-(2-Diazoacetyl)-5-methyl-1H-1,2,3-triazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,5-dimethylpyrimidine-2,4(1H,3H)-dione (5p)

Compound 5p was obtained in 78% (304 mg) yield according to the general procedure (enaminone 10p: 474 mg, 49 h). Light yellow powder, mp 189–189 °C (EtOH, decomp.). IR (ATR, ZnSe, cm–1): ν 2097 (N–N stretch), 1613, 1318, 1101. 1H NMR (400 MHz, DMSO-d6): δ 1.87 (s, 3H), 2.60 (s, 3H), 2.61–2.86 (m, 2H), 3.18 (s, 3H), 3.58–3.79 (m, 2H), 4.28 (d, J = 3.8 Hz, 1H), 5.16–5.27 (m, 1H), 5.33 (t, J = 5.1 Hz, 1H), 6.53 (t, J = 6.7 Hz, 1H), 6.72 (s, 1H), 7.87 (s, 1H). 13C{1H} NMR (101 MHz, DMSO-d6): δ 8.4, 12.9, 27.5, 37.0, 54.6, 57.3, 60.9, 84.6, 85.5, 108.6, 134.5, 136.6, 141.0, 150.6, 162.8, 180.2. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C16H20N7O5, 390.1520; found, 390.1537.

2-Diazo-1-(5-methyl-1,2,3-thiadiazol-4-yl)ethan-1-one (5q)

Compound 5q was obtained in 71% (119 mg) yield together with compound 4q in 2% (4 mg) yield according to the general procedure (enaminone 10q: 252 mg, 25 h). Light yellow needles, mp 95 °C (PE). IR (ATR, ZnSe, cm–1): ν 2101 (N–N stretch), 1603, 1478, 1344, 860. 1H NMR (600 MHz, DCCl3): δ 2.94 (s, 3H), 6.67 (s, 1H). 13C{1H} NMR (151 MHz, DCCl3): δ 10.9, 57.2, 154.2, 157.9, 180.0. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C5H5N4OS, 169.0179; found, 169.0176.

1-(3-(4-Chlorophenyl)-5-methylisoxazol-4-yl)-2-diazoethan-1-one (5r)

Compound 5r was obtained in 52% (136 mg) yield together with compound 4r in 44% (127 mg) yield according to the general procedure (enaminone 10r: 346 mg, 50 h). Light yellow oil, gradually crystallizing under a layer of PE, mp 83–85 °C. IR (ATR, ZnSe, cm–1): ν 3078, 2110 (N–N stretch), 1613, 1581, 1429, 1360, 1089, 851. 1H NMR (400 MHz, DCCl3): δ 2.70 (s, 3H), 5.04 (s, 1H), 7.50 (dd, J = 21.6, 8.5 Hz, 4H). 13C{1H} NMR (101 MHz, DCCl3): δ 13.2, 57.8, 114.8, 126.8, 129.3, 130.6, 136.7, 159.8, 173.8, 180. HRMS (ESI-TOF) m/z: [M + H]+ calcd for C12H9ClN3O2, 262.0378; found, 262.0394.

X-ray Structural Analysis

X-ray structural analysis of compounds 4f and 5c was performed on an Xcalibur 3 single-crystal diffractometer according to the standard method (Mo Kα radiation, graphite monochromator, 295(2) K, ω-scanning with a step of 1°). The structures were solved and refined using the SHELXTL software suite.[58] The structures were solved by the direct method with the ShelXS program, the structures were refined with the ShelXL program using a full-matrix method of least squares by F2 in anisotropic approximation for nonhydrogen atoms. The hydrogen atoms were placed in the calculated positions and included in the refinement according to the riding model. The complete X-ray structural data sets for compounds 4f and 5c were deposited at the Cambridge Crystallographic Data Center (deposition numbers CCDC 2091552 and CCDC 2091548, respectively).

Computational Methods

All mechanical quantum calculations were performed using Gaussian 09.[59] The geometries were fully optimized at the hybrid meta-generalized gradient approximation M06-2X/6-31G(d).[60,61] All minima intermediates were verified by the absence of negative eigenvalues in the vibrational frequency analysis. Transition-state structures were found using the Berny algorithm[62,63] and verified by vibrational analysis. The transition states were visualized by animating the negative eigenvector coordinate. Single-point energies of the optimized geometries were evaluated using the larger basis set M06-2X/6-311+G(d,p)[64−67] in the presence of a solvation model based on the density (SMD) solvation model using 1,4-dioxane or ethanol as a representative solvent medium.[68] The thermal corrections evaluated from the unscaled vibrational frequencies at the M06-2X/6-31G(d) level of theory were then added to the M06-2X/6-311+G(d,p) electronic energies to obtain the free energies. In order to determine the minimum energy path on the potential energy surface, IRC calculations, by defining the phase for the transition vector motion along the path, were performed for the identified transition states using the Hessian-based predictor-corrector integrator to confirm the reaction path proceeding in both directions (reactant and product), in which the Hessian was recomputed every three predictor steps with a step size along a reaction path of 0.05 bohr.[69−71] All energies reported in this paper are Gibbs free energies at 298.15 K using unscaled frequencies. All activation free energies are quoted relative to infinitely separated reagents. Optimized structures are illustrated using CYLview.[72]
  36 in total

1.  A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes.

Authors:  Vsevolod V Rostovtsev; Luke G Green; Valery V Fokin; K Barry Sharpless
Journal:  Angew Chem Int Ed Engl       Date:  2002-07-15       Impact factor: 15.336

2.  Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.

Authors:  Benjamin E Blass; Keith Coburn; Wenlin Lee; Neil Fairweather; Andrew Fluxe; Shengde Wu; John M Janusz; Michael Murawsky; Gina M Fadayel; Bin Fang; Michelle Hare; Jim Ridgeway; Ron White; Chris Jackson; Laurent Djandjighian; Richard Hedges; Fred C Wireko; Amanda L Ritter
Journal:  Bioorg Med Chem Lett       Date:  2006-06-21       Impact factor: 2.823

3.  A photolabile linker for the solid-phase synthesis of 4-substituted NH-1,2,3-triazoles.

Authors:  Katrine Qvortrup; Thomas E Nielsen
Journal:  Chem Commun (Camb)       Date:  2011-02-01       Impact factor: 6.222

4.  Distortion/interaction energy control of 1,3-dipolar cycloaddition reactivity.

Authors:  Daniel H Ess; K N Houk
Journal:  J Am Chem Soc       Date:  2007-08-09       Impact factor: 15.419

5.  Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions.

Authors:  Aleksandr V Marenich; Christopher J Cramer; Donald G Truhlar
Journal:  J Phys Chem B       Date:  2009-05-07       Impact factor: 2.991

6.  Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.

Authors:  Elisa Azzali; Diana Machado; Amit Kaushik; Federica Vacondio; Sara Flisi; Clotilde Silvia Cabassi; Gyanu Lamichhane; Miguel Viveiros; Gabriele Costantino; Marco Pieroni
Journal:  J Med Chem       Date:  2017-08-10       Impact factor: 7.446

7.  Rational design and synthesis of yellow-light emitting triazole fluorophores with AIE and mechanochromic properties.

Authors:  Qi Lai; Qing Liu; Kai Zhao; Chuan Shan; Lukasz Wojtas; Qingchuan Zheng; Xiaodong Shi; Zhiguang Song
Journal:  Chem Commun (Camb)       Date:  2019-04-16       Impact factor: 6.222

8.  A heteroleptic bis(tridentate) ruthenium(II) platform featuring an anionic 1,2,3-triazolate-based ligand for application in the dye-sensitized solar cell.

Authors:  Stephan Sinn; Benjamin Schulze; Christian Friebe; Douglas G Brown; Michael Jäger; Joachim Kübel; Benjamin Dietzek; Curtis P Berlinguette; Ulrich S Schubert
Journal:  Inorg Chem       Date:  2014-01-21       Impact factor: 5.165

9.  Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold.

Authors:  David Remillard; Dennis L Buckley; Hyuk-Soo Seo; Fleur M Ferguson; Sirano Dhe-Paganon; James E Bradner; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2019-09-13       Impact factor: 4.345

10.  Metal-Free Route for the Synthesis of 4-Acyl-1,2,3-Triazoles from Readily Available Building Blocks.

Authors:  Joice Thomas; Vince Goyvaerts; Sandra Liekens; Wim Dehaen
Journal:  Chemistry       Date:  2016-06-10       Impact factor: 5.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.